Skip to main content

Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis

Abstracts

Abstracts

  • Sunday, September 29, 2024
  • 8:00 AM – 8:10 AM ET
    100 - Primary Outcome Analysis for Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized, Phase III Trial of Hypo- vs. Conventionally Fractionated Regional Nodal Irradiation (RNI)
    Location: Room 202
    Presenter: Karen Hoffman, MD, FASTRO – MD Anderson Cancer Center
  • 8:10 AM – 8:20 AM ET
    101 - Long Term Rates of Lymphedema in Hypofractionated Nodal Regional Irradiation for Women with Breast Cancer: A Phase 2 Clinical Trial - "HeNRIetta"
    Location: Room 202
    Presenter: Alfredo Urdaneta, MD – Virginia Commonwealth University Health System
  • 8:20 AM – 8:30 AM ET
    102 - NOVEMBER, A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer
    Location: Room 202
    Presenter: Matthew Poppe, MD, FASTRO – University of Utah Huntsman Cancer Institute
  • 8:30 AM – 8:40 AM ET
    103 - Early Safety of Ultra-Hypofractionated Whole Breast Irradiation and Sequential Tumor Bed Boost for Early Breast Cancer (SHIFT): A Multicenter, Phase 2 Trial
    Location: Room 202
    Presenter: Siyue Zheng, MD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  • 8:40 AM – 8:50 AM ET
    104 - Conventional vs. Hypofractionated Proton Postmastectomy Radiotherapy: Patient Reported Outcomes from a Randomized Phase 2 Trial
    Location: Room 202
    Presenter: Muhammad Shuja, MD – Mayo Clinic Rochester
  • 8:50 AM – 9:00 AM ET
    Discussant
    Location: Room 202
    Discussant: Asal Rahimi, MD, MS – University of Texas Southwestern Medical Center
  • 8:00 AM – 8:10 AM ET
    105 - Phase I Clinical Trial of Lobaplatin Combined with Image-Guided Volume-Modulated Arc Radiation Therapy in Locally Advanced Cervical Cancer
    Location: Room 204
    Presenter: Jing You, MD
  • 8:10 AM – 8:20 AM ET
    106 - Early Assessment of Response Using ctDNA as a Non-Invasive Biomarker in Patients with Gynecologic Malignancies Undergoing Radiotherapy
    Location: Room 204
    Presenter: Gabriella Wernicke, MD, MS – Northwell Health Cancer Institute
  • 8:20 AM – 8:30 AM ET
    107 - Moderated Hypofractionated Online Adaptive Radiotherapy in Locally Advanced Cervical Cancer: A Prospective 1 Clinical Trial
    Location: Room 204
    Presenter: Zheng Zeng, MD – Peking Union Medical College Hospital
  • 8:30 AM – 8:40 AM ET
    108 - Acceleration of Overall Treatment Time by Mono-Application Multifractionated Brachytherapy over 48 Hours vs. Sequential Weekly Application Brachytherapy in Carcinoma Cervix - Multi-Institutional, Subc
    Location: Room 204
    Presenter: Krithikaa Sekar, MD, MBBS – Healthcare Global Enterprises Ltd.
  • 8:40 AM – 8:50 AM ET
    109 - Image Guided Brachytherapy Quality Assurance on NRG GY017, an NRG Oncology Clinical Trial Investigating the Sequencing of Immunotherapy and Chemoradiation for Locally Advanced Cervical Cancer
    Location: Room 204
    Presenter: Hayeon Kim, PhD – Magee Womens Hospital of University of Pittsburgh Medical Center and Hillman Cancer Center
  • 8:50 AM – 9:00 AM ET
    Discussant
    Location: Room 204
    Discussant: Scott Glaser, MD – City of Hope National Medical Center
  • 8:00 AM – 8:10 AM ET
    110 - Clinical Outcomes for Standard of Care Machine Learning Prostate Radiotherapy Treatment Planning
    Location: Room 147
    Presenter: Jeff Winter, PhD – University Health Network
  • 8:10 AM – 8:20 AM ET
    111 - DeepTuning: A Novel Deep Learning Approach for Interactive Plan Tuning and Trade-Off Exploration
    Location: Room 147
    Presenter: Lin Ma, PhD – Mayo Clinic College of Medicine and Science Rochester
  • 8:20 AM – 8:30 AM ET
    112 - Initial Clinical Experience of Cherenkov Imaging in Sub-Total Total Skin Electron Therapy Identifies Opportunities to Improve Daily Set-Up QA
    Location: Room 147
    Presenter: Brook Byrd, PhD, MS, BS – Penn Medicine Radiation Oncology Abramson Cancer Center
  • 8:30 AM – 8:40 AM ET
    113 - Individual Radiotherapy Plan Based on Multi-Omics Model Study for Cervical Cancer Patients with Ovarian Preservation
    Location: Room 147
    Presenter: Guang Li, PhD – Chongqing University Cancer Hospital
  • 8:40 AM – 8:50 AM ET
    114 - Results of a Dose Reconstruction Effort for a Large-Scale Retrospective Study on Late Health Effects Following Radiotherapy within the National Wilms Tumor Study
    Location: Room 147
    Presenter: Matthew Mille, PhD – National Cancer Institute
  • 8:50 AM – 9:00 AM ET
    115 - Multi-Institutional Standardized Dosimetry Protocol for Preclinical Radiobiological Experiments
    Location: Room 147
    Presenter: Stavros Melemenidis, PhD – Stanford University
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 207 B
  • 8:05 AM – 8:10 AM ET
    1000 - Impact of Prior Local Therapy (LT) on Treatment Response and Survival of Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC): A Pooled Analysis of COU-AA-302 and ACIS Trials
    Location: Room 207 B
    Presenter: Omar Azem, MD – Rush University Medical Center
  • 8:10 AM – 8:15 AM ET
    1001 - Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial
    Location: Room 207 B
    Presenter: Chia-Lin Tseng, MD – Sunnybrook Health Sciences Centre
  • 8:15 AM – 8:20 AM ET
    1002 - Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study
    Location: Room 207 B
    Presenter: Xin Qi, MD, MS – Peking University First Hospital
  • 8:20 AM – 8:25 AM ET
    1003 - Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)
    Location: Room 207 B
    Presenter: Savita Dandapani, MD, PhD – City of Hope Comprehensive Cancer Center
  • 8:25 AM – 8:30 AM ET
    1004 - Stereotactic Body Radiation Therapy (SBRT) Combined with Pelvic Radiotherapy and GTV Boost Based on Multiparameter Magnetic Resonance Image for High-Risk Prostate Cancer: A Phase II Study
    Location: Room 207 B
    Presenter: Ouying Yan
  • 8:30 AM – 8:35 AM ET
    1005 - A Prospective Pilot Study Investigating 18F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Pros
    Location: Room 207 B
    Presenter: Devaki Shilpa Surasi, MD – MD Anderson Cancer Center
  • 8:35 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 207 B
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 207 B
  • 1:00 PM – 1:10 PM ET
    2 - A Prospective, Phase II Study of 177Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort
    Location: Ballroom A/B/C
    Presenter: Kenneth Merrell, MD, MS – Mayo Clinic Alix School of Medicine
  • 1:10 PM – 1:20 PM ET
    3 - A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings
    Location: Ballroom A/B/C
    Presenter: Gabriella Macchia, MD – Responsible Research Hospital
  • 1:20 PM – 1:30 PM ET
    4 - Hypofractionated Whole-Breast Irradiation with Simultaneous Integrated Boost for Breast Cancer: Primary Analysis of the HYPOSIB-Trial (ARO 2013-05)
    Location: Ballroom A/B/C
    Presenter: David Krug, MD – University Hospital Hamburg-Eppendorf
  • 1:30 PM – 1:40 PM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Kimberly Corbin, MD – Mayo Clinic Alix School of Medicine
  • 1:40 PM – 1:50 PM ET
    5 - Pirfenidone in the Treatment of Radiation-Induced Lung Injury: A Randomized, Controlled, Multicenter Clinical Trial
    Location: Ballroom A/B/C
    Presenter: Ming Chen, MD – Sun Yat-Sen University Cancer Center
  • 1:50 PM – 2:00 PM ET
    LBA04 - Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial
    Location: Ballroom A/B/C
    Presenter: Vedang Murthy, MD – Tata Memorial Centre
  • 2:00 PM – 2:10 PM ET
    LBA05 - MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial
    Location: Ballroom A/B/C
    Presenter: Jay Detsky, MD, PhD – Sunnybrook Health Sciences Centre
  • 2:10 PM – 2:20 PM ET
    LBA06 - Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial
    Location: Ballroom A/B/C
    Presenter: Nicolas Demogeot, MD – Institut de Cancerologie de Lorraine
  • 2:20 PM – 2:30 PM ET
    LBA07 - A Multicenter Phase III Randomized Clinical Trial Comparing the Efficacy of an Adjuvant SOX Chemotherapy Regimen with SOX Combined with a Simultaneous Radiotherapy Regimen after D2 Radical Resection f
    Location: Ballroom A/B/C
    Presenter: Ou-ying Yan, MD – Cancer Center, West China Hospital, Sichuan University
  • 2:45 PM – 2:55 PM ET
    130 - MORF4L1-Mediated DNA Damage Repair Modulates cGAS-STING Activation and Radiosensitivity in Hepatocellular Carcinoma
    Location: Room 152
    Presenter: Siwei Wang, PhD – Department of Radiation Oncology, Cancer Center, Zhongshan Hospital, Fudan University
  • 2:55 PM – 3:05 PM ET
    131 - Unraveling the Mechanism behind Prophylactic Radiotherapy to Prevent Traumatic Heterotopic Ossification
    Location: Room 152
    Presenter: Meng-Lun Hsieh, DO, PhD – University of Texas Southwestern Medical Center
  • 3:05 PM – 3:15 PM ET
    132 - SnoRNAs and Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma
    Location: Room 152
  • 3:15 PM – 3:25 PM ET
    133 - The Impact of REXO4 Condensates on Irradiation-Induced Poly(ADP-ribosyl)ation and Tumor Radioresistance
    Location: Room 152
    Presenter: Xin-Juan Fan
  • 3:25 PM – 3:35 PM ET
    134 - O-GlcNAcylation of PRDX1 and Radiation Resistance in Non-Small Cell Lung Cancer via Suppressing TRIM21 Mediated Ubiquitination
    Location: Room 152
    Presenter: Ran Zhang, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University
  • 3:35 PM – 3:45 PM ET
    135 - USP15 and Radiation-Induced DNA Damage Repair of Intestinal Epithelial Cells by Deubiquitinating and Stabilizing ATM
    Location: Room 152
    Presenter: Ruiqiu Zhu, MD, PhD – Soochow University
  • 2:45 PM – 2:50 PM ET
    Introduction
    Location: Room 158
  • 2:50 PM – 2:55 PM ET
    1006 - The Impact of an Outpatient Urgent Care Clinic in Patients Treated for Head and Neck Cancer
    Location: Room 158
    Presenter: Elliott Czarnecki, MD – Henry Ford Hospital
  • 2:55 PM – 3:00 PM ET
    1007 - Efficacy of Quantitative Targeted Exercise Combined with Full-Scale Refined Nutrition Management for Improving Nutrition in Patients with Head and Neck Cancer Receiving Radiotherapy - A Randomized Con
    Location: Room 158
    Presenter: Juanli Shi – Xijing Hospital Air Force Medical University
  • 3:00 PM – 3:05 PM ET
    1008 - The HEART Team Protocol: A Strategic Approach to High-Risk Patient Management in Adult Oncology to Reduce Emergency Room Visits and Hospital Admissions
    Location: Room 158
    Presenter: Yun Jeong Seo, DNP – Mount Sinai West
  • 3:05 PM – 3:10 PM ET
    1009 - Efficacy and Safety of a Dexamethasone-Free Antiemetic Regimen for Nausea and Emesis Prevention during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC
    Location: Room 158
    Presenter: Ya Liu, MD
  • 3:10 PM – 3:15 PM ET
    1010 - Development of a Program Utilizing the Simple Measure of Gobbledygook (SMOG) Algorithm for Comprehending Patient-Generated Educational Content in the Field of Radiation Oncology
    Location: Room 158
    Presenter: Walter Chin, MS, BSN – Emory Clinic
  • 3:15 PM – 3:20 PM ET
    1011 - Education and Resource Needs of Financial Advocacy Staff Serving Radiation Oncology Patients
    Location: Room 158
    Presenter: Francinna Scott-Jones, CPAR, ROCC, FACCC – Northside Hospital
  • 3:20 PM – 3:40 PM ET
    Questions and Answers
    Location: Room 158
  • 3:40 PM – 3:45 PM ET
    Closing
    Location: Room 158
  • 2:45 PM – 2:55 PM ET
    136 - Examining the Impact of Combined P53 Status and PD-L1 Expression on Vulvar Cancer Outcomes
    Location: Room 207 B
    Presenter: Baher Elgohari, MD, MS, MBBS – UPMC Hillman Cancer Center
  • 2:55 PM – 3:05 PM ET
    137 - The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy
    Location: Room 207 B
    Presenter: Zohaib Sherwani, MD – Rutgers Cancer Institute of New Jersey
  • 3:05 PM – 3:15 PM ET
    138 - The Prognostic Value of Pretreatment Carbohydrate Antigen 125 Level in Cervical Cancer Patients Treated with Definitive Radiotherapy or Concurrent Chemoradiotherapy
    Location: Room 207 B
    Presenter: Dingchao Liu, MD – Peking Union Medical College Hospital
  • 3:15 PM – 3:25 PM ET
    139 - Longitudinal Dynamic MRI Radiomic Models for Early Prediction of Prognosis in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
    Location: Room 207 B
    Presenter: Chang Cai, BS
  • 3:25 PM – 3:35 PM ET
    140 - Incidence of Cervical Cancer Subtypes in Relation to HPV Vaccination Uptake in the U.S.
    Location: Room 207 B
    Presenter: Peter Lee, MD, PhD – Fox Chase Cancer Center
  • 3:35 PM – 3:45 PM ET
    141 - Effect of Cisplatin Cycles on Prognosis for Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy: A Long-Term Follow-Up, Large Cohort Study
    Location: Room 207 B
    Presenter: Zheng Zeng, MD – Peking Union Medical College Hospital
  • 3:45 PM – 3:55 PM ET
    Discussant
    Location: Room 207 B
    Discussant: Eric Donnelly, MD – Northwestern Memorial Hospital
  • 2:45 PM – 2:55 PM ET
    123 - Efficacy of Kangfuxin Liquid Retention Enema in Preventing and Treating Radiation-Induced Proctitis in Cervical Cancer Patients: A Randomized, Open-Label, Phase III Study
    Location: Room 151
    Presenter: Xiaojing Yang, PhD – Shanghai Sixth People's Hospital
  • 2:55 PM – 3:05 PM ET
    124 - Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial
    Location: Room 151
    Presenter: Aiden Kooyman, BS – University of British Columbia
  • 3:05 PM – 3:15 PM ET
    125 - Impact of Clinical Target Volume Utilization on Outcomes in Patients with Non-Spine Bone Oligometastases Treated with Stereotactic Ablative Radiation Therapy
    Location: Room 151
    Presenter: Emily O'Reilly, MD, BS – BC Cancer - Vancouver Centre
  • 3:15 PM – 3:25 PM ET
    126 - Real-world implementation of simulation-free radiotherapy (SFRT-1000): A propensity score-matched analysis of 1000 consecutive palliative courses delivered in routine care
    Location: Room 151
    Presenter: Thilo Schuler, MD, MHInf – Northern Sydney Cancer Centre - Royal North Shore Hospital
  • 3:25 PM – 3:35 PM ET
    127 - Applying Deep Learning Based Facial Age Phenotyping to Improve Life Expectancy Prediction in Metastatic Cancer Patients Receiving Palliative Radiotherapy
    Location: Room 151
    Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
  • 3:35 PM – 3:45 PM ET
    128 - Relationship between Cannabis Use and Opioid Use in Patients with Cancer Metastatic to Bone in a Large Multicenter Cohort from a State with Legalized Adult Non-Medical Cannabis
    Location: Room 151
    Presenter: Matthew Cousins, MD, PhD – Self Regional Healthcare
  • 3:45 PM – 3:55 PM ET
    129 - Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320)
    Location: Room 151
    Presenter: Slavisa Tubin, MD – MedAustron, Center for Ion Therapy and Research
  • 2:45 PM – 2:55 PM ET
    116 - Patient-Reported Functional Decline Following Active Surveillance (AS), Radical Prostatectomy (RP), External Beam Radiation without Androgen Deprivation Therapy (EBRT w/o ADT), or Low-Dose-Rate Brachy
    Location: Room 204
    Presenter: Patrick Carriere, MD, PhD – MD Anderson Cancer Center
  • 2:55 PM – 3:05 PM ET
    117 - A Prospective Interventional Clinical Trial (MC1732): Characterization of Thoracic Chemoradiotherapy-Related Cardiac Changes Using an Implantable Cardiac Monitor (ICM)
    Location: Room 204
    Presenter: Joshua Niska, MD – Mayo Clinic Arizona
  • 3:05 PM – 3:15 PM ET
    118 - Effectiveness of Nurse-Led Multimodal Rehabilitation for Patients Undergoing Postoperative Radiotherapy of Esophageal Cancer: A Randomized Controlled Trial
    Location: Room 204
    Presenter: Xianyan Chen, MD, PhD – West China Hospital of Sichuan University
  • 3:15 PM – 3:25 PM ET
    119 - From Face-to-Face to Digital Spaces: A Critical Look at Patient Satisfaction with Telehealth in Cancer Care
    Location: Room 204
    Presenter: Bailey Loving, MD – Beaumont Health - Royal Oak
  • 3:25 PM – 3:35 PM ET
    120 - Comparing Radiation and Systemic Therapy Patients Longitudinal Satisfaction of a Cloud-Based Bidirectional App Used for Real-Time Communication of Patient-Reported Cancer Treatment Symptoms
    Location: Room 204
    Presenter: Ian Kudel, PhD – Varian Medical Systems
  • 3:35 PM – 3:45 PM ET
    121 - Randomized Trial of Mindfulness during Radiation Therapy
    Location: Room 204
    Presenter: Elsa Sutton, MD – Mayo Clinic Rochester
  • 3:45 PM – 3:55 PM ET
    122 - Symptom Monitoring with Patient-Reported Outcomes during Definitive Radiation Treatment
    Location: Room 204
    Presenter: Ann Raldow, MD, MPH – UCLA Radiation Oncology
  • 4:45 PM – 4:55 PM ET
    148 - Proton Craniospinal Irradiation for Patients with Solid Tumor Leptomeningeal Metastasis- Final Analysis of a Phase II Study
    Location: Room 147
    Presenter: Jonathan Yang, MD, PhD – New York University School of Medicine
  • 4:55 PM – 5:05 PM ET
    149 - Risk of Radiation Myelitis after Hypofractionated Spine Stereotactic Body Radiation Therapy
    Location: Room 147
    Presenter: Christopher Jackson, MD, MS – Memorial Sloan Kettering Cancer Center
  • 5:05 PM – 5:15 PM ET
    150 - Evaluating Neurocognitive Recovery Following Stereotactic Radiosurgery and Whole Brain Radiation Therapy: Insights from a Pooled Analysis of Three Phase III Trials
    Location: Room 147
    Presenter: Hua-Ren Cherng, MD – University of Maryland Medical Center
  • 5:15 PM – 5:25 PM ET
    151 - Neurocognition and Quality of Life for Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity vs. Whole-Brain Radiotherapy (WBRT) Following Brain Metastasis Resection - Results of
    Location: Room 147
    Presenter: Rami El Shafie, MD – University Medical Center Gottingen (UMG)
  • 5:25 PM – 5:35 PM ET
    152 - A Longitudinal Study to Correlate Neurocognitive Changes of IDH-Mutant and IDH-Wildtype Glioma Patients after Chemoradiotherapy with Changes on Resting-State MRI
    Location: Room 147
    Presenter: Zhihua Liu, PhD – Washington University School of Medicine in St Louis
  • 5:35 PM – 5:45 PM ET
    153 - Assessing Atrophy and Neurocognitive Decline in Hippocampal Subfields after Fractionated Brain Radiation Therapy
    Location: Room 147
    Presenter: Hieu Nguyen, BS – UCSD School of Medicine
  • 5:45 PM – 5:55 PM ET
    Discussant
    Location: Room 147
    Discussant: Kristin Redmond, MD, MPH – Johns Hopkins University
  • 4:45 PM – 4:55 PM ET
    154 - A Randomized Controlled Crossover Trial to Evaluate the Efficacy of AI-Assisted Heart Contouring
    Location: Room 207 B
    Presenter: Danielle Bitterman, MD – Brigham and Women's Hospital
  • 4:55 PM – 5:05 PM ET
    155 - Novel Statistical-AI Method to Automate Discovery of Predictive Factors and Thresholds for 3 Year Survival, Dysphagia and Xerostomia for Patients with Head and Neck Cancers
    Location: Room 207 B
    Presenter: Charles Mayo, PhD, FASTRO, FAAPM – University of Michigan
  • 5:05 PM – 5:15 PM ET
    156 - The Fragility of Phase III Trials in Oncology
    Location: Room 207 B
    Presenter: Yufei Liu, MD, PhD – City of Hope National Medical Center
  • 5:15 PM – 5:25 PM ET
    157 - I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer
    Location: Room 207 B
    Presenter: Maliazurina Saad, PhD – MD Anderson Cancer Center
  • 5:25 PM – 5:35 PM ET
    158 - Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study
    Location: Room 207 B
    Presenter: Zhi Yang, MD
  • 5:35 PM – 5:45 PM ET
    159 - Explainable MRI-Based Deep Learning Model for Predicting EGFR Mutation in NSCLC Brain Metastases: Advancing Clinical Prognosis and Oncological Treatment Decisions
    Location: Room 207 B
    Presenter: Che-yu Hsu, MD, PhD, MS – National Taiwan University Hospital
  • 4:45 PM – 4:55 PM ET
    142 - A Phase II Trial of Camrelizumab in Combination with Concurrent Chemoradiotherapy as First-Line Treatment for Betel Nut-Related Locally Advanced Oral Squamous Cell Carcinoma
    Location: Room 152
    Presenter: Feng Liu, MD – Hunan Cancer Hospital
  • 4:55 PM – 5:05 PM ET
    143 - Contralateral Neck Recurrence Rates in Head and Neck Carcinomas after Primary Surgery, Bilateral Neck Dissection, a Pathologically Negative Contralateral Neck, and Adjuvant Ipsilateral Neck Radiation
    Location: Room 152
    Presenter: Kendall Kiser, MD, MS – Washington University/B-JH/SLCH Consortium
  • 5:05 PM – 5:15 PM ET
    144 - Phase II Trial of Proton Re-Irradiation+/-Chemotherapy in Previously Irradiated Recurrent Head/Neck Cancer
    Location: Room 152
    Presenter: Nancy Lee, MD, FASTRO – Memorial Sloan Kettering Cancer Center
  • 5:15 PM – 5:25 PM ET
    145 - Acupuncture for (Chemo)Radiotherapy - Related Dysphagia in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase 2 Study
    Location: Room 152
    Presenter: Pierluigi Bonomo, MD – Azienda Ospedaliera Universitaria Careggi
  • 5:25 PM – 5:35 PM ET
    146 - Opioid Therapy vs. Multimodal Analgesia in Head and Neck Cancer (OPTIMAL-HN): Results of a Randomized Clinical Trial
    Location: Room 152
    Presenter: Sondos Zayed, MD, MPH, FRCPC – University of Ottawa at The Ottawa Hospital
  • 5:35 PM – 5:45 PM ET
    147 - Long Term Effects of Cognitive Behavioral Therapy on Late Toxicities, Depressive and Anxiety Symptoms in Patients with Locoregional Advanced Nasopharyngeal Carcinoma Undergoing Chemoradiotherapy: A Ra
    Location: Room 152
    Presenter: Feng Liu, MD – Hunan Cancer Hospital
  • 5:45 PM – 5:55 PM ET
    Discussant
    Location: Room 152
    Discussant: Christina Henson, MD – University of Oklahoma Health Sciences Center
  • Monday, September 30, 2024
  • 8:00 AM – 8:10 AM ET
    165 - Long-Term Prognostic Analysis of Chemoradiotherapy vs. Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results from a Prospective Randomized Control Study
    Location: Room 151
    Presenter: Xiaxi Qiao, MD
  • 8:10 AM – 8:20 AM ET
    166 - Combination of Radiotherapy and Nivolumab for Previously Treated Advanced Gastric Cancer (CIRCUIT Trial): 3-Years Update
    Location: Room 151
    Presenter: Yoshiyuki Suzuki, MD, PhD – Fukushima Medical University
  • 8:20 AM – 8:30 AM ET
    167 - Personalized Minimal Residual Disease Profiling Predicts Prognosis in Esophageal Carcinoma Undergoing Definitive Radiotherapy
    Location: Room 151
    Presenter: Lin-rui Gao, MD – Chinese Academy of Medical Sciences and Peking Union Medical College
  • 8:30 AM – 8:40 AM ET
    168 - Neoadjuvant Toripalimab plus Concurrent Chemoradiotherapy in the Locally Advanced Adenocarcinoma of Esophagogastric Junction: A Phase II Trial
    Location: Room 151
    Presenter: Rongxu Du, MD – Beijing Cancer Hospital
  • 8:40 AM – 8:50 AM ET
    169 - Quality of Life Among Long-Term Survivors of Oesophageal Cancer Cured By Definitive Radiotherapy: A Cross-Sectional Study
    Location: Room 151
    Presenter: Qingsong Pang, MD, PhD – Tianjin Cancer Hospital
  • 8:50 AM – 9:00 AM ET
    Discussant
    Location: Room 151
    Discussant: Abraham Wu, MD – Memorial Sloan Kettering Cancer Center
  • 8:00 AM – 8:10 AM ET
    170 - Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial
    Location: Room 204
    Presenter: Christopher Jackson, MD, MS – Memorial Sloan Kettering Cancer Center
  • 8:10 AM – 8:20 AM ET
    171 - Whole Lung Irradiation in Rhabdomyosarcoma with Lung Metastases: A Report from the Soft Tissue Sarcoma Committee of the Childrens Oncology Group
    Location: Room 204
    Presenter: Leo Luo, MD – Vanderbilt University Medical Center
  • 8:20 AM – 8:30 AM ET
    172 - Establishing the Association between OAR Dose and Post-Therapy Scholastic Performance in Pediatric Brain Tumor Survivors
    Location: Room 204
    Presenter: Raymond Mailhot Vega, MD, MPH – University of Florida Proton Therapy Institute
  • 8:30 AM – 8:40 AM ET
    173 - Interplay of Radiation and Cyclophosphamide Doses on Local Control in Children with Group III Rhabdomyosarcoma: An Analysis of Studies from the Childrens Oncology Group
    Location: Room 204
    Presenter: Margaret Kozak, MD – UT Southwestern Medical Center
  • 8:40 AM – 8:50 AM ET
    174 - Stereotactic Body Radiation Therapy (SBRT) for Metastatic Osteosarcoma: Local Control Outcomes with Local Failure Dosimetric Analysis
    Location: Room 204
    Presenter: Jenna Kocsis, MD – Cleveland Clinic Taussig Cancer Center
  • 8:50 AM – 9:00 AM ET
    Discussant
    Location: Room 204
    Discussant: Paul Aridgides, MD – SUNY Upstate Medical University
  • 8:00 AM – 8:10 AM ET
    160 - Convection-Enhanced Drug Delivery and Radiosensitization for Diffuse Midline Glioma
    Location: Room 144
    Presenter: Matthew Gallitto, MD, PhD – Columbia University Irving Medical Center
  • 8:10 AM – 8:20 AM ET
    161 - Exploring the Combined Effects of Tamoxifen and Radiotherapy, Regardless of Estrogen Receptor Status
    Location: Room 144
  • 8:20 AM – 8:30 AM ET
    162 - A Precision Oncology Platform to Target CDK4/6 Inhibitor Resistance
    Location: Room 144
    Presenter: Kamal Pandey, PhD – UT Southwestern Medical Center at Dallas
  • 8:30 AM – 8:40 AM ET
    163 - Novel Radiosensitizer Screen Identifies an Effective Strategy to Treat p53 Wild-Type Breast Cancer Models in a Hormone Independent Manner
    Location: Room 144
    Presenter: Reine Abou Zeidane, MD – Case Western Reserve School of Medicine
  • 8:40 AM – 8:50 AM ET
    164 - Synergistic Potential of CDK4/6 Inhibitors and Radiotherapy with Anti-PD-L1 Immunotherapy in Triple-Negative Breast Cancer
    Location: Room 144
    Presenter: Wen-Chi Yang, MD – National Taiwan University Hospital
  • 8:50 AM – 9:00 AM ET
    Discussant
    Location: Room 144
    Discussant: Nadeem Riaz, MD, MS – Memorial Sloan Kettering Cancer Center
  • 8:00 AM – 8:10 AM ET
    175 - Unlocking the Simulation-Omitted Spine SAbR: Advancing Efficiency with Advanced CBCT and Online Adaptive Therapy
    Location: Room 152
    Presenter: Da Wang, PhD – UT Southwestern Medical Center
  • 8:10 AM – 8:20 AM ET
    176 - Enabling Conventional Single-Energy CT Systems to Incorporate Dual-Energy CT Functionalities by Multimodality Deep Learning
    Location: Room 152
    Presenter: Lei Xing, PhD, FASTRO – Stanford University
  • 8:20 AM – 8:30 AM ET
    177 - MRI for Spinal Cord Visualization near Surgical Hardware to Replace CT Myelogram for Spine Sarcoma Radiotherapy
    Location: Room 152
    Presenter: Soon Huh, PhD – University of Florida Proton Therapy Institute
  • 8:30 AM – 8:40 AM ET
    178 - CT-Ventilation Using Swin UNETR Networks for Automated Lobe Segmentation
    Location: Room 152
    Presenter: Gabriela Oliveira Nomura, BS – Dell Seton Medical Center at the University of Texas
  • 8:40 AM – 8:50 AM ET
    179 - Results of a Prospective Trial to Evaluate Novel Lung Function Imaging for Lung Cancer Surgery
    Location: Room 152
    Presenter: Lydia Wilson, PhD – Thomas Jefferson University
  • 8:50 AM – 9:00 AM ET
    180 - Assessing the Tumor Visibility and Respiratory Motion of Liver Cancer Patients on Multi-Task MR and 4D-CT Imaging for Radiation Treatment Planning
    Location: Room 152
    Presenter: Oi Wai Chau, PhD – Mayo Clinic Alix School of Medicine
  • 10:45 AM – 10:55 AM ET
    214 - Transgender and Non-Binary Use of Gender-Affirming Hormone Therapy and Effects on PSA and Prostate Cancer Detection
    Location: Room 140
    Presenter: Paul Riviere, MD – UCSD Radiation Medicine and Applied Sciences
  • 10:55 AM – 11:05 AM ET
    215 - Centering Black Voices: Factors Influencing a Cancer Patients Decision to Join a Clinical Trial
    Location: Room 140
    Presenter: Charlyn Gomez, BS – University of Maryland School of Medicine
  • 11:05 AM – 11:15 AM ET
    216 - Identification of a High-Risk Population in the United States for Anti-EBV Serologic Screening for Nasopharyngeal Carcinoma
    Location: Room 140
    Presenter: Payton Clark, BS – Cleveland Clinic Foundation
  • 11:15 AM – 11:25 AM ET
    217 - Cancer Screening Knowledge and Interest in Incarcerated Women
    Location: Room 140
    Presenter: Bradley Eckelmann, MD, PhD – University of Wisconsin Hospitals and Clinics
  • 11:25 AM – 11:35 AM ET
    218 - Paid Medical Leave and Mortality Risk in Working Cancer Survivors
    Location: Room 140
    Presenter: Abigail Kohut-Jackson, BS, MBS – Saint Louis University School of Medicine
  • 11:35 AM – 11:45 AM ET
    218a - Can Radiotherapy Quality Assurance (RT QA) Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries (LMICs) - Technical Results of the Second Phase of a Prospective International Ato
    Location: Room 140
    Presenter: June Corry, MD – GenesisCare
  • 11:45 AM – 11:55 AM ET
    Discussant
    Location: Room 140
    Discussant: Vonetta Williams, MD, PhD – Memorial Sloan Kettering Cancer Center
  • 10:45 AM – 10:55 AM ET
    181 - Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus
    Location: Room 202
    Presenter: Karen Hoffman, MD, FASTRO – MD Anderson Cancer Center
  • 10:55 AM – 11:05 AM ET
    182 - Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
    Location: Room 202
    Presenter: Noelia Sanmamed, MD, PhD – Hospital Clinico San Carlos
  • 11:05 AM – 11:15 AM ET
    183 - Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher - Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials
    Location: Room 202
    Presenter: Martin King, MD, PhD – Brigham and Womens Hospital
  • 11:15 AM – 11:25 AM ET
    184 - A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High Risk Prostate Cancer: Efficacy Results at Median 6 Y
    Location: Room 202
    Presenter: Juanita Crook, MD – BCCancer
  • 11:25 AM – 11:35 AM ET
    185 - Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial
    Location: Room 202
    Presenter: Comron Hassanzadeh, MD, MPH – MD Anderson Cancer Center
  • 11:35 AM – 11:45 AM ET
    186 - Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses
    Location: Room 202
    Presenter: Colin Belliveau, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)
  • 11:45 AM – 11:55 AM ET
    187 - Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial
    Location: Room 202
    Presenter: John Michael Bryant, MD – Moffitt Cancer Center
  • 10:45 AM – 10:55 AM ET
    202 - Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma prior to CAR T-Cell Therapy
    Location: Room 144
    Presenter: Omran Saifi, MD – Mayo Clinic Florida
  • 10:55 AM – 11:05 AM ET
    204 - Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome
    Location: Room 144
    Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center
  • 11:05 AM – 11:15 AM ET
    205 - Multi-Institutional Update on Salvage Radiation Therapy in Relapsed/Refractory Large B Cell Lymphoma Patients in Post-CAR T Cell Therapy Failure
    Location: Room 144
    Presenter: Chirayu Patel, MD, MD, MPH – Massachusetts General Hospital
  • 11:15 AM – 11:25 AM ET
    206 - Does CAR T-Cell Level during Post-CART DLBCL Progression Influence the Response to Salvage Radiotherapy and Patient Outcomes?
    Location: Room 144
    Presenter: Jiaqi Fan, MD – University Cologne
  • 11:25 AM – 11:35 AM ET
    207 - Phase I Hypofractionation Trial of Relapsed/Refractory Lymphoma: Preliminary Results
    Location: Room 144
    Presenter: Greeshma Rajeev-Kumar, MD – University of Chicago Medicine
  • 11:35 AM – 11:45 AM ET
    203 - Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma - First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG)
    Location: Room 144
    Presenter: Michael Oertel, MD – University Hospital of Muenster
  • 11:45 AM – 11:55 AM ET
    Discussant
    Location: Room 144
    Discussant: John Plastaras, MD, PhD – University of Pennsylvania
  • 10:45 AM – 10:55 AM ET
    188 - Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
    Location: Room 207
    Presenter: Emily Lebow, MD – University of Pennsylvania
  • 10:55 AM – 11:05 AM ET
    189 - Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)
    Location: Room 207
    Presenter: Hui Liu, MD, PhD – Sun Yat-Sen University Cancer Center
  • 11:05 AM – 11:15 AM ET
    190 - The Selective Personalized RadioImmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes
    Location: Room 207
    Presenter: Nitin Ohri, MD, MS – Montefiore Einstein Comprehensive Cancer Center
  • 11:15 AM – 11:25 AM ET
    191 - Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: FLARE-RT Mature Outcomes and Patterns of Failure
    Location: Room 207
    Presenter: Sunan Cui, PhD – University of Washington
  • 11:25 AM – 11:35 AM ET
    192 - A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
    Location: Room 207
    Presenter: Nikhil Kotha, MD – Stanford Radiation Oncology
  • 11:35 AM – 11:45 AM ET
    193 - Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial
    Location: Room 207
    Presenter: Wen Bin Shen, MD – The Fourth Hospital of Hebei Medical University
  • 11:45 AM – 11:55 AM ET
    194 - Simultaneous Integrated Boost vs. Conventional Radiotherapy for Patients with Limited-Stage Small Cell Lung Cancer: A Randomized, Non-Inferiority, Open-Label, Phase 3 Trial
    Location: Room 207
    Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
  • 10:45 AM – 10:55 AM ET
    208 - Assessment of Circulating Tumor Cells in Oligometastatic Castration-Sensitive Prostate Cancer Patients from the ORIOLE Trial
    Location: Room 150
    Presenter: Soha Bazyar, MD, PhD – University of Maryland
  • 10:55 AM – 11:05 AM ET
    209 - Does Detection of Tumor-Associated Mutations in Proximal Lymph Predict Relapse in HPV-Negative Head and Neck Cancer Patients?
    Location: Room 150
    Presenter: Aadel Chaudhuri, MD, PhD – Mayo Clinic Alix School of Medicine
  • 11:05 AM – 11:15 AM ET
    210 - Associations Between Genetic Alterations in Follicular Lymphoma and Radiosensitivity
    Location: Room 150
    Presenter: N. Ari Wijetunga, MD, PhD, MS – University of North Carolina
  • 11:15 AM – 11:25 AM ET
    211 - Prognostic Implications of Cerebrospinal Fluid Circulating Tumor DNA (CSF ctDNA) Following Radiation Therapy in Patients with Leptomeningeal Metastasis: Analysis of a Randomized Phase II Trial
    Location: Room 150
    Presenter: Alexander Goglia, MD, PhD – Memorial Sloan Kettering Cancer Center
  • 11:25 AM – 11:35 AM ET
    212 - Characterizing Radiation Induced Subclonal Kinetics in Pancreatic Ductal Adenocarcinoma
    Location: Room 150
    Presenter: Vincent Bernard Pagan, MD, PhD – MD Anderson Cancer Center
  • 11:35 AM – 11:45 AM ET
    213 - Circulating Tumor Cell-Based Molecular Biomarkers of 177Lu-PSMA-617 Treatment Efficacy in Metastatic Prostate Cancer
    Location: Room 150
    Presenter: David Miyamoto, MD, PhD – Massachusetts General Hospital
  • 11:45 AM – 11:55 AM ET
    Discussant
    Location: Room 150
    Discussant: Kent Mouw, MD, PhD – Dana-Farber/Brigham and Women's Cancer Center
  • 10:45 AM – 10:55 AM ET
    195 - A Deep Learning-Driven Framework for Large Language Model-Assisted Automatic Target Volume Localization and Delineation for Enhancing Spinal Metastases Stereotactic Body Radiotherapy Workflow
    Location: Room 145
    Presenter: Zi Yang, PhD – Stanford University
  • 10:55 AM – 11:05 AM ET
    196 - Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Lung Cancer: Multicenter Deep Learning Model Development and Prospective Validation
    Location: Room 145
    Presenter: Zeliang Ma, MD – Mayo Clinic Rochester
  • 11:05 AM – 11:15 AM ET
    197 - SAM-ART: An Efficient Segmentation Method with a Large Vision Model for MRI-Guided Adaptive Radiotherapy
    Location: Room 145
    Presenter: Bining Yang, PhD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy
  • 11:15 AM – 11:25 AM ET
    198 - Deep Learning-Based Quick MLC Sequencing for MRI-Guided Online Adaptive Radiotherapy
    Location: Room 145
    Presenter: Ahmet Ahunbay, BS – Medical College of Wisconsin
  • 11:25 AM – 11:35 AM ET
    199 - A Reinforcement Learning Approach to Automate Breast Radiation Therapy Treatment Planning Using Electronic Compensation (ECOMP)
    Location: Room 145
    Presenter: Dongrong Yang, MS, BS – Duke University Medical Center
  • 11:35 AM – 11:45 AM ET
    200 - Automated Treatment Planning with Deep Reinforcement Learning for Head-and-Neck Cancer Intensity Modulated Radiation Therapy
    Location: Room 145
    Presenter: Dongrong Yang, MS, BS – Duke University Medical Center
  • 11:45 AM – 11:55 AM ET
    201 - Gross Tumor Volume Auto Delineation Based on a Novel Multimodal Adaptive Segmentation Model in Multicenter Nasopharyngeal Carcinoma Radiotherapy
    Location: Room 145
    Presenter: Hongfei Sun, PhD
  • 1:30 PM – 1:40 PM ET
    1 - A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
    Location: Ballroom A/B/C
    Presenter: Matthew Poppe, MD, FASTRO – University of Utah Huntsman Cancer Institute
  • 1:40 PM – 1:50 PM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Kathleen Horst, MD – Stanford University
  • 1:50 PM – 2:00 PM ET
    LBA01 - Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer
    Location: Ballroom A/B/C
    Presenter: Jason Efstathiou, MD, PhD, FASTRO – Massachusetts General Hospital
  • 2:00 PM – 2:10 PM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Curtiland Deville, MD, FASTRO – Johns Hopkins University
  • 2:10 PM – 2:20 PM ET
    LBA02 - Concurrent Chemoradiation +/- Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005
    Location: Ballroom A/B/C
    Presenter: Kristin Higgins, MD – City of Hope Atlanta
  • 2:20 PM – 2:30 PM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Robert Samstein, MD, PhD – Icahn School of Medicine at Mount Sinai
  • 2:30 PM – 2:40 PM ET
    LBA03 - Interim Futility Results of NRG-HN005, A Randomized, Phase II/III Non-Inferiority Trial for Non-Smoking p16+ Oropharyngeal Cancer Patients
    Location: Ballroom A/B/C
    Presenter: Sue Yom, MD, PhD, FASTRO – UCSF Bakar Precision Medicine Cancer Center
  • 2:40 PM – 2:50 PM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Sewit Teckie, MD, MBA – New York City Health and Hospitals
  • 3:00 PM – 3:10 PM ET
    219 - Renal Function after Definitive Local Therapy for Primary Renal Cell Carcinoma: A Meta-Analysis
    Location: Room 207
    Presenter: Nicholas Zaorsky, MD, MS – University Hospitals Case Medical Center
  • 3:10 PM – 3:20 PM ET
    220 - Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer
    Location: Room 207
  • 3:20 PM – 3:30 PM ET
    221 - Exploratory Analyses of Stereotactic Ablative Radiotherapy for Bladder Preservation in Elderly Bladder Cancer Patients: Phase I Results
    Location: Room 207
    Presenter: Yun Bai, MD – Peking University First Hospital
  • 3:30 PM – 3:40 PM ET
    222 - Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer
    Location: Room 207
    Presenter: Yash Soni, MD, BS – UT Southwestern Medical Center
  • 3:40 PM – 3:50 PM ET
    223 - Oncological Outcomes and Toxicities of Brachytherapy for Carcinomas of the Penis: A Bi-Centric Study by the SFRO Brachytherapy Group
    Location: Room 207
    Presenter: Kanta Ka, MD, MS – Gustave Roussy Cancer Center
  • 3:50 PM – 4:00 PM ET
    224 - Natural History after Likely Cure vs. Recurrence vs. after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials
    Location: Room 207
    Presenter: Soumyajit Roy, MS, MBBS – Rush University Medical Center
  • 3:00 PM – 3:10 PM ET
    231 - Failure Modes and Root Cause Analysis for CBCT-Guided Online Adaptive Radiotherapy of the Pelvis
    Location: Room 209
    Presenter: Dandan Zheng, PhD – University of Rochester
  • 3:10 PM – 3:20 PM ET
    232 - Optimized Hybrid Model for Radiation Incident Reporting in Multi-Site Centers
    Location: Room 209
    Presenter: Xing Li, PhD – Inova Schar Cancer Institute
  • 3:20 PM – 3:30 PM ET
    233 - Peer Review Implementation: From Chart Rounds to the Bedside
    Location: Room 209
    Presenter: Chad Caraway, MS – Eastern Virginia Medical School
  • 3:30 PM – 3:40 PM ET
    234 - Analysis of Protocol Deviations at a Large Multi-Center Academic Radiation Oncology Department to Improve Patient Safety
    Location: Room 209
    Presenter: Manav Shah, BS – Northwell Health
  • 3:40 PM – 3:50 PM ET
    235 - Enhancing Patient Safety in Radiotherapy with a Novel AI-Powered Risk Management Tool
    Location: Room 209
    Presenter: Evangelos Pappas, PhD – University of West Attica
  • 3:50 PM – 4:00 PM ET
    236 - "If You're Talking, I Think You're Muted:" Follow-Up Analysis of Weekly Peer Review Discussion and Deviation Detection after Transitioning from Virtual to In-Person Format
    Location: Room 209
    Presenter: Ryan Hughes, MD – Wake Forest University School of Medicine
  • 3:00 PM – 3:10 PM ET
    225 - Early Clinical Insights into FDG-Guided Radiotherapy Planning and Delivery on a Novel PET-Linac Platform in Patients with Lung and Bone Lesions: Pioneering Real-Time Biology-Guided Radiotherapy
    Location: Room 145
    Presenter: Bin Cai, PhD – University of Texas Southwestern Medical Center
  • 3:10 PM – 3:20 PM ET
    226 - Toward Adaptive Dose Painting with Hypoxia Biomarkers: Feasibility of Oxygen-Enhanced (OE)-MRI T1 Mapping on Low-Field MR-Linac
    Location: Room 145
    Presenter: Claire Park, PhD, BS – Memorial Sloan Kettering Cancer Center
  • 3:20 PM – 3:30 PM ET
    227 - Pathologic Response Prediction Value of 18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
    Location: Room 145
    Presenter: Yuchun Wei, MD, PhD – Shandong Cancer Hospital and Institute
  • 3:30 PM – 3:40 PM ET
    228 - Evaluating the Efficacy of Novel MET-Targeting Camelid Derived Antibody as an Imaging Agent in Head and Neck Cancers
    Location: Room 145
    Presenter: Rachel Minne, MS, BS – University of Wisconsin School of Medicine and Public Health
  • 3:40 PM – 3:50 PM ET
    229 - APTw Imaging for Personalized Target Delineation of Glioblastoma
    Location: Room 145
    Presenter: Patrick Tang, MSc – Erasmus MC Cancer Institute
  • 3:50 PM – 4:00 PM ET
    230 - Feasibility of Biology-Guided Radiotherapy with Gallium-68 PSMA-11 Radiotracer for Bony Metastases in Prostate Cancer Patients
    Location: Room 145
    Presenter: Chunhui Han, PhD – City of Hope National Medical Center
  • 3:00 PM – 3:05 PM ET
    Introduction
    Location: Room 143
  • 3:05 PM – 3:10 PM ET
    1012 - Changes in Employment and Practice Locations among Radiation Oncologists: 2015 - 2023
    Location: Room 143
    Presenter: Sifan Lu, BA – Maimonides Medical Center/SUNY Downstate HSU
  • 3:10 PM – 3:15 PM ET
    1013 - High Deductible Health Plans and Survival among Cancer Survivors and the Role of Cost-Driven Delayed or Forgone Medical Care
    Location: Room 143
    Presenter: Justin Barnes, MD, MS – Washington University School of Medicine
  • 3:15 PM – 3:20 PM ET
    1014 - Radiotherapy Utilization and Spending in Patients with Traditional Medicare Compared to Medicare Advantage
    Location: Room 143
    Presenter: Jacob Hogan, BS – Washington University in St. Louis School of Medicine
  • 3:20 PM – 3:25 PM ET
    1016 - Hypofractionated Radiotherapy for Prostate Cancer: Preliminary Results from the HypoAfrica Study
    Location: Room 143
    Presenter: Adedayo Joseph, MD – Lagos University Teaching Hospital
  • 3:25 PM – 3:30 PM ET
    1017 - Trends and Variation in Spending for Radiation Treatment Episodes for Medicare Patients with Cancer
    Location: Room 143
    Presenter: Miranda Lam, MD, MBA – Brigham and Women's Hospital/Dana-Farber
  • 3:30 PM – 3:55 PM ET
    Question and Answers
    Location: Room 143
  • 3:55 PM – 4:00 PM ET
    Closing
    Location: Room 143
  • 5:00 PM – 5:10 PM ET
    237 - Five vs. Three Fractions of Prone Accelerated Partial Breast Irradiation: Results of a Randomized Controlled Phase 3 Non-Inferiority Trial
    Location: Room 202
    Presenter: Naamit Gerber, MD – NYU Langone Medical Center
  • 5:10 PM – 5:20 PM ET
    238 - Single-Institution Phase 1/2 Prospective Trial Evaluating Three-Fraction Partial Breast Irradiation: Four Year Outcomes Including Quantitative Cosmesis and Patient-Reported Outcomes
    Location: Room 202
    Presenter: Silpa Raju, MD – Washington University in St. Louis
  • 5:20 PM – 5:30 PM ET
    239 - Clinical Outcomes of Patients with Early-Stage Breast Cancer Treated with Five-Fraction Partial Breast Irradiation vs. Intraoperative Radiation Therapy
    Location: Room 202
    Presenter: Anirudh Bommireddy, MD – Anirudh Bommireddy
  • 5:30 PM – 5:40 PM ET
    240 - Long-Term Results of a Phase II Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone Sensitive Breast Cancer
    Location: Room 202
    Presenter: David Lakomy, MD – Washington University in St. Louis
  • 5:40 PM – 5:50 PM ET
    241 - Comparison of Acute and Late Toxicities with Daily vs. Every Other Day Five Fraction Partial Breast Radiation Therapy
    Location: Room 202
    Presenter: Sean Parker, MD – Cleveland Clinic Health System
  • 5:50 PM – 6:00 PM ET
    Discussant
    Location: Room 202
    Discussant: Chirag Shah, MD – Cleveland Clinic
  • 5:00 PM – 5:10 PM ET
    252 - Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma
    Location: Room 144
    Presenter: Christina Huang, MD, MS – Duke University School of Medicine
  • 5:10 PM – 5:20 PM ET
    253 - Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia
    Location: Room 144
    Presenter: Jeffrey Wong, MD, FASTRO – City of Hope National Medical Center
  • 5:20 PM – 5:30 PM ET
    254 - Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Childrens Oncology Group AHOD 0431
    Location: Room 144
    Presenter: Sarah Milgrom, MD – University of Colorado Denver
  • 5:30 PM – 5:40 PM ET
    255 - Initial Results of the Multicenter Phase II Trial of a Novel Hypofractionated Low-Dose Radiotherapy for Indolent Non-Hodgkin Lymphoma
    Location: Room 144
    Presenter: Xinyue Wang, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  • 5:40 PM – 5:50 PM ET
    256 - A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort
    Location: Room 144
    Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center
  • 5:50 PM – 6:00 PM ET
    Discussant
    Location: Room 144
    Discussant: Hans Theodor Eich, MD, PhD – University of Muenster
  • 5:00 PM – 5:10 PM ET
    242 - Long-Term Outcomes of Postoperative Radiotherapy for Patients with pIIIA-N2 Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
    Location: Room 207
    Presenter: Yu Men, MD – CICAMS and PUMC
  • 5:10 PM – 5:20 PM ET
    243 - Long-Term Outcomes of a Prospective Randomized Trial of Passive Scattering Proton Therapy vs. Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
    Location: Room 207
    Presenter: Tingshi Su, MD, PhD – MD Anderson Cancer Center
  • 5:20 PM – 5:30 PM ET
    244 - The Impact of Prophylactic Bisphosphonates on Radiation-Induced Rib Fractures and Chest Wall Pain in Peripheral Lung Tumor SBRT: A Randomized, Double-Blind, Placebo-Controlled Study
    Location: Room 207
    Presenter: Michael Farris, MD – Wake Forest University Medical Center
  • 5:30 PM – 5:40 PM ET
    245 - Incidence of Pulmonary Hypertension and Association with Pulmonary Artery Radiation Dose in Lung Cancer Radiotherapy
    Location: Room 207
    Presenter: Katelyn Atkins, MD, PhD – Cedars-Sinai Medical Center
  • 5:40 PM – 5:50 PM ET
    246 - Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC
    Location: Room 207
    Presenter: Narek Shaverdian, MD – Memorial Sloan Kettering Cancer Center
  • 5:00 PM – 5:10 PM ET
    247 - A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes
    Location: Room 143
    Presenter: John Nikitas, MD – UCLA Radiation Oncology
  • 5:10 PM – 5:20 PM ET
    248 - The Impact of Hypofractionated Pre-Operative Radiation Therapy on PD-L1 Expression in Soft Tissue Sarcomas
    Location: Room 143
    Presenter: Manpreet Bedi, MD, MS – Medical College of Wisconsin Affiliated Hospitals
  • 5:20 PM – 5:30 PM ET
    249 - Habitat Escalated Adaptive Therapy (HEAT): A Phase 2 Trial Utilizing Radiomic Habitat-Directed and Genomic-Adjusted Radiation Dose (GARD) Optimization for High-Grade Soft Tissue Sarcoma
    Location: Room 143
    Presenter: Arash Naghavi, MD, MS – H. Lee Moffitt Cancer Center and Research Institute
  • 5:30 PM – 5:40 PM ET
    250 - Reduction of Bone Fracture after Radiotherapy in Lower Extremity Soft Tissue Sarcoma after Implementing Bone Avoidance Objectives for Radiotherapy Planning
    Location: Room 143
    Presenter: David Kirsch, MD, PhD, FASTRO – Princess Margaret Cancer Centre
  • 5:40 PM – 5:50 PM ET
    251 - Immune Profiling of "Radvax" Abscopal Responses in Metastatic Melanoma Patients Progressing on Anti-PD1 Therapy Treated with Hypofractionated Radiotherapy (HFRT) to One Lesion Combined with Pembrolizu
    Location: Room 143
    Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
  • 5:50 PM – 6:00 PM ET
    Discussant
    Location: Room 143
    Discussant: B. Ashleigh Guadagnolo, MD, FASTRO, MPH – MD Anderson Cancer Center
  • 5:00 PM – 5:05 PM ET
    Introduction
    Location: Room 152
  • 5:05 PM – 5:10 PM ET
    1018 - Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) and 60 Gy in 15 Fractions for Advanced Head and Neck Cancers: An Interim Analysis of a Phase I Trial
    Location: Room 152
    Presenter: Musaddiq Awan, MD – Medical College of Wisconsin
  • 5:10 PM – 5:15 PM ET
    1019 - Neoadjuvant Chemoimmunotherapy Followed by Surgery and Response-Adapted Adjuvant Radiotherapy for Head and Neck Squamous Cell Carcinoma
    Location: Room 152
    Presenter: Yuan Wu, MD – Hubei Cancer Hospital
  • 5:15 PM – 5:20 PM ET
    1020 - Oxygen-Enhanced MRI in Patients with p16-Positive Oropharyngeal Cancer Undergoing (Chemo)-Radiotherapy
    Location: Room 152
    Presenter: James Price, MBBS, FRCR – The Christie NHS Foundation Trust
  • 5:20 PM – 5:25 PM ET
    1021 - Prognostic Value of Image-Identified Extranodal Extension and Potential Role in Cn Classification in HPV-Negative Oropharyngeal Cancer: A Multi-Center Cohort Study
    Location: Room 152
    Presenter: Shao Hui Huang, MS, RT – Princess Margaret Cancer Centre
  • 5:25 PM – 5:30 PM ET
    1022 - ACRIN 6685 PET-CT Threshold to Reinterpret Pre-Treatment Head and Neck Cancer (HNC) Imaging? Stage Migration and Treatment Outcomes
    Location: Room 152
    Presenter: Nuverah Mohsin, MD, BS – Fox Chase Cancer Center
  • 5:30 PM – 5:35 PM ET
    1023 - Treatment Response-Adapted Risk Index Model for Survival Prediction and Adjuvant Chemotherapy Selection in Nonmetastatic Nasopharyngeal Carcinoma
    Location: Room 152
    Presenter: Yang Liu, MD – Cancer Hospital Chinese Academy of Medical Sciences
  • 5:35 PM – 5:55 PM ET
    Questions and Answers
    Location: Room 152
  • 5:55 PM – 6:00 PM ET
    Closing
    Location: Room 152
  • 5:00 PM – 5:05 PM ET
    Introduction
    Location: Room 147
  • 5:05 PM – 5:10 PM ET
    1024 - CT-Guided Online Adaptive Stereotactic Body Radiation Therapy for Liver Tumors
    Location: Room 147
    Presenter: Alexander Lukez, MD – Fox Chase Cancer Center
  • 5:10 PM – 5:15 PM ET
    1025 - Establishment of a Trigger Decision Model for Cervical Cancer in Real-Time Online Adaptive Radiotherapy
    Location: Room 147
    Presenter: Chenying Ma, MD, PhD – The First Affiliated Hospital of Soochow University
  • 5:15 PM – 5:20 PM ET
    1026 - Fast Tracking MR Only Adaptive Radiotherapy; Automatic Segmentation on Planning, Daily MRI and Synthetic CT
    Location: Room 147
    Presenter: Asma Amjad, PhD – Medical College of Wisconsin
  • 5:20 PM – 5:25 PM ET
    1027 - Optimizing Adaptive Radiation Therapy for Cervical Cancer: When is the Best Time to Adapt and Who Benefits the Most
    Location: Room 147
    Presenter: Asya Pitre, BA – Texas College of Osteopathic Medicine
  • 5:25 PM – 5:30 PM ET
    1028 - Comparison of MRI-Linac to Standalone MRI Volumes in Glioblastoma: Implications for Adaptive Radiotherapy and Contrast Imaging
    Location: Room 147
    Presenter: Kaylie Cullison, PhD, BS – University of Miami Sylvester Comprehensive Cancer Center
  • 5:30 PM – 5:35 PM ET
    1029 - Integrating Laser Surface Mapping with CBCT for Enhanced Decision Support from ML Guided Resimulation Predictions
    Location: Room 147
    Presenter: Stephen Shang, PhD – South Florida Proton Therapy Institute
  • 5:35 PM – 5:55 PM ET
    Questions and Answers
    Location: Room 147
  • 5:55 PM – 6:00 PM ET
    Closing
    Location: Room 147
  • Tuesday, October 1, 2024
  • 8:00 AM – 8:10 AM ET
    257 - Risk Factors Correlated with Brain Metastases Risk in Limited-Stage Small Cell Lung Cancer
    Location: Room 147
    Presenter: Li Li, MD, PhD, RT – Shandong Cancer Hospital and Institute
  • 8:10 AM – 8:20 AM ET
    258 - Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small
    Location: Room 147
    Presenter: Aaron Seo, MD, PhD – MD Anderson Cancer Center
  • 8:20 AM – 8:30 AM ET
    259 - Phase I Trial of Concurrent Talazoparib and Consolidative Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
    Location: Room 147
    Presenter: Benjamin Lok, MD – Princess Margaret Cancer Centre
  • 8:30 AM – 8:40 AM ET
    260 - Consolidative Stereotactic Radiotherapy in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer Receiving First-Line Third-Generation EGFR Tyrosine Kinase Inhibitors: A Prospective Phase II Trial
    Location: Room 147
    Presenter: Yue Zhou, MD – Fudan University
  • 8:40 AM – 8:50 AM ET
    261 - A Phase II Trial of Stereotactic Body Radiotherapy (SBRT) in Patients with Stage IV Oncogene-Driven Non-Small Cell Lung Cancer (NSCLC)
    Location: Room 147
    Presenter: Florence Keane, MD – Massachusetts General Hospital
  • 8:50 AM – 9:00 AM ET
    262 - External Validation of Oligometastatic Genomic Signature in Non-Small Cell Lung Cancer Patients
    Location: Room 147
    Presenter: Ariel Choi, MD – Wake Forest Baptist Medical Center
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 158
  • 8:05 AM – 8:10 AM ET
    1042 - Radiation Oncologist Workload after Traditional Office Hours: A Threat to Work-Life Balance?
    Location: Room 158
    Presenter: Marc Gaudet, MD – The Ottawa Hospital, University of Ottawa
  • 8:10 AM – 8:15 AM ET
    1043 - Department Wellbeing is Improved after a Process Improvement on Call Workflow Optimization
    Location: Room 158
    Presenter: Claire Baniel, MD – Stanford University
  • 8:15 AM – 8:20 AM ET
    1044 - TEAMRO: Final Analysis of TEAMRO (TEAching Mentorship in Radiation Oncology), A Multicenter Prospective Phase 2 Intervention Study on Teaching Mentorship Skills to Resident Physicians Working with Med
    Location: Room 158
    Presenter: Anurag Saraf, MD – Brigham and Women's Hospital/Dana-Farber
  • 8:20 AM – 8:25 AM ET
    1045 - Patterns of Contouring Mistakes in the Novice Resident: A Qualitative Analysis to Guide Future Educational Efforts
    Location: Room 158
    Presenter: Megan Orr, MD – UC San Diego Health
  • 8:25 AM – 8:30 AM ET
    1046 - AI Auto Contouring and Its Impact on Resident Education
    Location: Room 158
    Presenter: Alexander Qian, MD – University of California San Francisco
  • 8:30 AM – 8:35 AM ET
    1047 - Optimizing Leadership Development Strategies for Enhanced Leader and Team Impact
    Location: Room 158
    Presenter: Amanda Woods, PhD – The University of Texas MD Anderson Cancer Center
  • 8:35 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 158
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 158
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 140
  • 8:05 AM – 8:10 AM ET
    1037 - ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer
    Location: Room 140
    Presenter: Mylin Torres, MD, FASTRO – Emory University
  • 8:10 AM – 8:15 AM ET
    1036 - Phase 2 Trial of Stereotactic MR-Guided Adaptive Radiation Therapy in One Fraction (SMART ONE)
    Location: Room 140
    Presenter: Michael Chuong, MD – Miami Cancer Institute
  • 8:15 AM – 8:20 AM ET
    1038 - Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with
    Location: Room 140
    Presenter: Xinyan Xu, MD – MD Anderson Cancer Center
  • 8:20 AM – 8:25 AM ET
    1039 - Identifying Patients with Bone Metastases at Highest Risk of Skeletal-Related Events and Understanding Underuse of Bone Modifying Agents: A Retrospective Analysis
    Location: Room 140
    Presenter: Lakshmi Rekha Narra, MD – Rutgers Cancer Institute of New Jersey
  • 8:25 AM – 8:30 AM ET
    1040 - Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Ca
    Location: Room 140
    Presenter: Subhadip Das, MD – BC Cancer Surrey and University of British Columbia
  • 8:30 AM – 8:35 AM ET
    1041 - Progress in Shortening Treatment Courses for Bone Metastases in a Statewide Quality Consortium
    Location: Room 140
    Presenter: Luke Higgins, MD – University of Michigan
  • 8:35 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 140
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 140
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 152
  • 8:05 AM – 8:10 AM ET
    1030 - Hypoxia Detection in Prostate Cancer with Oxygen-Enhanced BOLD MRI
    Location: Room 152
    Presenter: Martin Swinton, MBBChir – The Christie NHS Foundation Trust
  • 8:10 AM – 8:15 AM ET
    1031 - Using Virtual Monoenergetic Images and Electron Density (Rho) Images from Photon-Counting CT (PCCT) for Radiation Therapy (RT) Dose Calculation: A Comparison Study
    Location: Room 152
    Presenter: Xin Wu, MS – Duke University Medical Center
  • 8:15 AM – 8:20 AM ET
    1032 - Comparison of Enhanced Cone-Beam CT Using Next Generation Reconstruction with Deep Learning-Based Synthetic CT for Adaptive Radiotherapy in Pelvic Cancers
    Location: Room 152
    Presenter: Eenas Omari, PhD, DABR – Medical College of Wisconsin
  • 8:20 AM – 8:25 AM ET
    1033 - A Clinical Evaluation of Spiral 4DCT and Intelligent 4DCT Sequence Scanning
    Location: Room 152
    Presenter: Yao Hao, PhD – Washington University in St. Louis
  • 8:25 AM – 8:30 AM ET
    1034 - Impact of Synthetic PET Evaluation prior to PET-Guided Functional Modeling in Optimizing Patient Selection for Biology-Guided Radiotherapy
    Location: Room 152
    Presenter: Daniel Hicks, MD – Yale New Haven Hospital
  • 8:30 AM – 8:35 AM ET
    1035 - Precision Radiotherapy for Hepatocellular Carcinoma: Exploring the Clinical Utility of Functional Liver Avoidance Planning
    Location: Room 152
    Presenter: Afua Yorke, PhD – University of Washington
  • 8:35 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 152
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 152
  • 12:45 PM – 12:50 PM ET
    Introduction
    Location: Room 144
  • 12:50 PM – 12:55 PM ET
    1064 - Beyond Involved-Site Radiotherapy: NRG, COG, Alliance, ECOG-ACRIN, SWOG and CCTG Consensus Nomenclature for Radiation Targets on NCTN Lymphoma Trials
    Location: Room 144
    Presenter: Bradford Hoppe, MD, FASTRO, MPH – Mayo Clinic Florida
  • 12:55 PM – 1:00 PM ET
    1060 - The Effect of Palliative Radiotherapy Field Volume on Rates of Significant Hematologic Toxicity in Patients with Multiple Myeloma
    Location: Room 144
    Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center
  • 1:00 PM – 1:05 PM ET
    1061 - Optimizing Low Dose Radiotherapy for Indolent Lymphomas: Comparing 4 Gy x 2 vs. 2 Gy x 2
    Location: Room 144
    Presenter: Jessica Burlile, MD – Mayo Clinic College of Medicine and Science Rochester
  • 1:05 PM – 1:10 PM ET
    1059 - Detection of Early Cardiotoxicity after Anthracyclines and Mediastinal Radiotherapy Using Cardiac PET/MRI
    Location: Room 144
    Presenter: Georgios Ntentas, DPhil – Guy's and St Thomas' NHS Foundation Trust
  • 1:10 PM – 1:15 PM ET
    1062 - Radiation-Related Late Toxicities Following Total Marrow Irradiation Transplant Conditioning Regimens
    Location: Room 144
    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center
  • 1:15 PM – 1:20 PM ET
    1063 - Radiate Equity: The Inclusion of Radiation Oncology and Other Specialities in Lymphoma Collaborative Groups
    Location: Room 144
    Presenter: Omran Saifi, MD – Mayo Clinic Florida
  • 1:20 PM – 1:40 PM ET
    Questions and Answers
    Location: Room 144
  • 1:40 PM – 1:45 PM ET
    Closing
    Location: Room 144
  • 12:45 PM – 12:50 PM ET
    Introduction
    Location: Room 140
  • 12:50 PM – 12:55 PM ET
    1054 - Prospective Four Year Single Institution Outcomes of 1.5 Tesla MR Linac Based Radiotherapy from the MOMENTUM Study
    Location: Room 140
    Presenter: Aronne Schottstaedt, MD, MS – MCWAH
  • 12:55 PM – 1:00 PM ET
    1055 - Prostate Cancer Survivors Long-Term Supportive Care Needs: Results from a Population-Based Cohort
    Location: Room 140
    Presenter: Yahui Xie, BA – University of Kansas Cancer Center
  • 1:00 PM – 1:05 PM ET
    1056 - Association between NCCN Distress Thermometer Screening Data and Natural Language Processing-Identified Toxicities during Radiotherapy
    Location: Room 140
    Presenter: Michelle Zhao, BA – UCSF
  • 1:05 PM – 1:10 PM ET
    1057 - Early Detection of Radiation-Induced Cardiotoxicity in Patients Receiving Thoracic Radiation
    Location: Room 140
    Presenter: Steven Montalvo, MD – UT Southwestern Medical Center
  • 1:15 PM – 1:40 PM ET
    Questions and Answers
    Location: Room 140
  • 1:35 PM – 1:45 PM ET
    1058 - Quality of Life after Ablative 5-Fraction Radiation Therapy from the Phase 2 SMART Pancreas Trial
    Location: Room 140
    Presenter: Michael Chuong, MD – Miami Cancer Institute
  • 1:40 PM – 1:45 PM ET
    Closing
    Location: Room 140
  • 12:45 PM – 12:55 PM ET
    277 - The Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events Following Modern Breast Radiotherapy
    Location: Room 207
    Presenter: Michael Roumeliotis, PhD – Johns Hopkins University
  • 12:55 PM – 1:05 PM ET
    278 - A Virtual Program for Fatigue among Women Undergoing Radiation Treatment: Results from a Randomized Controlled Basket Trial
    Location: Room 207
    Presenter: Erin Gillespie, MD, MPH – University of Washington-Fred Hutchinson Cancer Center
  • 1:05 PM – 1:15 PM ET
    279 - Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer: The TENDANCE Multicentric French Study (Trastuzumab-Deruxtecan and Concurrent Radiation Therap
    Location: Room 207
    Presenter: Kamel Debbi, MD – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII
  • 1:15 PM – 1:25 PM ET
    280 - Characterization of Skin Microbiome Profile before and during Radiation Therapy and Its Correlation to the Occurrence and Severity of Radiation Dermatitis
    Location: Room 207
    Presenter: Roxolyana Abdah-Bortnyak, MD – Rambam Health Care Campus
  • 1:25 PM – 1:35 PM ET
    281 - A Phase I/II Trial of Spectrophotometric Skin Changes during and after Radiotherapy and Correlation with Radiation-Induced Skin Toxicity in Breast Cancer Patients with Skin of Color
    Location: Room 207
    Presenter: Juhi Purswani, MD – New York University School of Medicine
  • 1:35 PM – 1:45 PM ET
    282 - Analysis of Rib Fracture Risk after Breast Radiation with Various Dose Fractionations
    Location: Room 207
    Presenter: Jackson Howell, MD – University of Utah Huntsman Cancer Institute
  • 1:45 PM – 1:55 PM ET
    Discussant
    Location: Room 207
    Discussant: Youlia Kirova, MD – Institut Curie
  • 12:45 PM – 12:55 PM ET
    283 - Measuring the Integration of Stereotactic Ablative Radiotherapy plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes
    Location: Room 147
    Presenter: Vivian Tan, MD – London Health Sciences Centre
  • 12:55 PM – 1:05 PM ET
    284 - A Phase II Randomized Trial of Radical Resection vs. Stereotactic Body Radiation Therapy (SBRT) in Patients with Operable Stage I Non-Small Cell Lung Cancer (NSCLC): Final Report Of RTOG-F3502
    Location: Room 147
    Presenter: Feng-Ming Kong, MD, PhD, FASTRO, FACR – University of Hong Kong
  • 1:05 PM – 1:15 PM ET
    285 - A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer
    Location: Room 147
    Presenter: Mark Farrugia, MD, PhD – Roswell Park Cancer Institute
  • 1:15 PM – 1:25 PM ET
    286 - Dosimetric Outcomes of SBRT to Ultracentral Lung Tumors: Lessons from the SUNSET Trial
    Location: Room 147
    Presenter: Rohan Salunkhe, MD, MBBS – Princess Margaret Cancer Center, University Health Network
  • 1:25 PM – 1:35 PM ET
    287 - Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: Final Results from a Nonrandomized Contr
    Location: Room 147
    Presenter: Percy Lee, MD, FASTRO – City of Hope National Medical Center
  • 1:35 PM – 1:45 PM ET
    288 - A Phase I Study of Cyclical Hypofractionated Palliative Radiation (Quad Shot) for Lung Tumors in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC): Results from the PROMISE 006 Trial
    Location: Room 147
    Presenter: Helen Zhang, MD – Memorial Sloan Kettering Cancer Center
  • 1:45 PM – 1:55 PM ET
    Discussant
    Location: Room 147
    Discussant: Clifford Robinson, MD, FASTRO – Washington University School of Medicine in St. Louis
  • 12:45 PM – 12:55 PM ET
    263 - The Eclipse-Radiotherapy Combined with ICI Orchestrates CD8+ T Cell- and NK Cell-Dependent Anti-Tumor Efficacy against Bulky Tumors
    Location: Room 150
    Presenter: Ren Luo, MD, PhD – West China Hospital of Sichuan University
  • 12:55 PM – 1:05 PM ET
    264 - Tumor Immunity Following Radiopharmaceutical + Checkpoint Blockade Varies with Treatment Sequence, Radioisotope and Tumor Immunogenicity
    Location: Room 150
    Presenter: Caroline Kerr, PhD – University of Wisconsin-Madison
  • 1:05 PM – 1:15 PM ET
    265 - Combining Proton Radiation Therapy and Mesothelin-Targeting Chimeric Antigen Receptor T-cell Therapy to Improve Outcomes in Pancreatic Cancer
    Location: Room 150
    Presenter: Uri Amit, MD, PhD, MPH – Tel Aviv Sourasky Medical Center- Ichilov Hospital
  • 1:15 PM – 1:25 PM ET
    266 - A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy
    Location: Room 150
    Presenter: Benjamin Schrank, MD, PhD – MD Anderson Cancer Center
  • 1:25 PM – 1:35 PM ET
    267 - Tilting Immunometabolic Balance of Tumor Microenvironment by Targeting ENO1 in KRAS-Mutated Colorectal and Pancreatic Cancers
    Location: Room 150
    Presenter: K. S. Clifford Chao, MD – China Medical University Hospital
  • 1:35 PM – 1:45 PM ET
    268 - The Role of RIPK1 in Mediating Enhanced Immune Responses Following Radiotherapy
    Location: Room 150
    Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association
  • 1:45 PM – 1:55 PM ET
    269 - Radiation-Induced TREM2-Expression on Tumor-Associated Macrophages Is a Target for Modulation of Immune Responses in Prostate Cancer
    Location: Room 150
    Presenter: Janny Villa-Pulgarin, PhD – Weill Cornell Medical College
  • 12:45 PM – 12:55 PM ET
    270 - Quantitative DW-MRI Monitoring of Metastatic Lymph Nodes in HPV+ Head and Neck Cancer Using MR-Linac
    Location: Room 152
    Presenter: Dina El-Habashy, MD, MS – Corewell Health William Beaumont University Hospital
  • 12:55 PM – 1:05 PM ET
    271 - Assessing Multi-Modality Imaging of Radiation Damage to Bone Marrow through Rigid Registration and Deformable Image Registration
    Location: Room 152
    Presenter: Carolyn Eckrich, MS, BS – University of Wisconsin
  • 1:05 PM – 1:15 PM ET
    272 - Impact of Organ-at-Risk (OAR) Radiation Dosimetry on Acute and Late Toxicity after Prostate Stereotactic Body Radiation Therapy (SBRT): A Post-Hoc Analysis of a Phase III Randomized Clinical Trial of
    Location: Room 152
    Presenter: Beth Neilsen, MD, PhD – University of California Los Angeles
  • 1:15 PM – 1:25 PM ET
    273 - Redefining Breast Cancer Tumor Size Classification through Big Data Analytics: A New Approach to Enhancing Prognostic Accuracy and Personalized Treatment
    Location: Room 152
    Presenter: Bin Feng, MS, BS – Chongqing University Cancer Hospital
  • 1:25 PM – 1:35 PM ET
    274 - Evaluation of Immune System Plasticity with a Multi-Compartment Model of Immuno-Positron Emission Tomography
    Location: Room 152
    Presenter: William Watkins, PhD – City of Hope National Medical Center
  • 1:35 PM – 1:45 PM ET
    275 - Patterns of Response in HNSCC Subregions Using Daily Quantitative MRI from MR-Guided Radiation Therapy
    Location: Room 152
    Presenter: Ryan Bonate, BS – Medical College of Wisconsin
  • 1:45 PM – 1:55 PM ET
    276 - Radiogenomic Deep Ensemble Learning for Identifying Radionecrosis Following Brain Metastasis Stereotactic Radiosurgery (SRS)
    Location: Room 152
    Presenter: Jingtong Zhao, MS, BS – Duke University
  • 2:30 PM – 2:35 PM ET
    Introduction
    Location: Room 140
  • 2:35 PM – 2:40 PM ET
    1048 - Bridging Prediction and Causality: Deciphering Clinical Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation via Multitask Machine Learning and Causal Inference of Proto
    Location: Room 140
    Presenter: Sang Ho Lee, PhD – University of Pennsylvania
  • 2:40 PM – 2:45 PM ET
    1049 - Deep Learning Based Facial Age Phenotyping in a Large-Scale, Real-World Cancer Patient Population
    Location: Room 140
    Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
  • 2:45 PM – 2:50 PM ET
    1050 - Predicting Acute Care Visits during Radiation Therapy with Machine Learning and Natural Language Processing
    Location: Room 140
    Presenter: Sarah Hampson, MD – University of California San Francisco
  • 2:50 PM – 2:55 PM ET
    1051 - Pulmonary Vessel Dosimetry and Morphological Re-Modeling after Thoracic Radiation Therapy
    Location: Room 140
    Presenter: Christian Guthier, PhD, MS – Brigham and Womens Hospital
  • 2:55 PM – 3:00 PM ET
    1052 - Predicting Pulmonary Toxicity in Lung Cancer Patients with Interstitial Lung Disease Receiving SABR Using Machine Learning: A Secondary Analysis of ASPIRE-ILD
    Location: Room 140
    Presenter: Matthew Gil, MSc – National Health Service
  • 3:00 PM – 3:10 PM ET
    Discussant
    Location: Room 140
    Discussant: Andrew Hope, MD – Princess Margaret Cancer Center / University of Toronto
  • 3:10 PM – 3:25 PM ET
    Questions and Answers
    Location: Room 140
  • 3:25 PM – 3:30 PM ET
    Closing
    Location: Room 140
  • 2:30 PM – 2:35 PM ET
    Introduction
    Location: Room 151
  • 2:35 PM – 2:40 PM ET
    1066 - Adjuvant Primary Site Radiation Therapy for Melanoma in the Immunotherapy Era
    Location: Room 151
    Presenter: Andrew Arifin, MD – London Health Sciences Centre
  • 2:40 PM – 2:45 PM ET
    1067 - Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era
    Location: Room 151
    Presenter: Stephanie Dudzinski, MD, PhD – MD Anderson Cancer Center
  • 2:45 PM – 2:50 PM ET
    1068 - Hypofractionated Radiation Therapy for Unresectable or Bulky Metastatic Melanoma
    Location: Room 151
    Presenter: Devarati Mitra, MD, PhD – MD Anderson Cancer Center
  • 2:50 PM – 2:55 PM ET
    1069 - Preoperative Hypofractionated Radiotherapy with Locoregional Hyperthermia in Recurrent and Radiation-Associated Sarcomas: Final Results of a Phase 2 Clinical Trial
    Location: Room 151
    Presenter: Mateusz SpaÅ‚ek, MD, DSc, PhD, MBA – Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy w Warszawie
  • 2:55 PM – 3:00 PM ET
    1070 - Long-Term Outcomes following Proton-Based Radiation Therapy for Pediatric Chordomas and Chondrosarcomas of the Mobile Spine and the Sacrum
    Location: Room 151
    Presenter: Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital
  • 3:00 PM – 3:05 PM ET
    1065 - Use of the 40-Gene Expression Profile (40-GEP) Test to Identify Immune Suppressed Patients with Brigham and Womens Hospital (BWH) T1-T2a Cutaneous Squamous Cell Carcinoma (cSCC) at Higher Risk of Meta
    Location: Room 151
    Presenter: Shlomo Koyfman, MD – Cleveland Clinic Foundation
  • 3:05 PM – 3:25 PM ET
    Questions and Answers
    Location: Room 151
  • 3:25 PM – 3:30 PM ET
    Closing
    Location: Room 151
  • 2:30 PM – 2:40 PM ET
    302 - Does Radiation Boost Dose Affect Organ Preservation Rates? A Secondary Analysis of the OPRA Trial
    Location: Room 150
    Presenter: Orly Yariv, MD – National Cancer Inst
  • 2:40 PM – 2:50 PM ET
    304 - Phase II Trial of Organ Preservation Program Using Short-Course Radiation and Folfoxiri for Rectal Cancer (SHORT-FOX): Clinical Response Outcomes
    Location: Room 150
    Presenter: Erqi Pollom, MD, MS – Stanford University
  • 2:50 PM – 3:00 PM ET
    305 - The New Sandwich Total Neoadjuvant Treatment (TNT) Strategy in Locally Advanced Rectal Cancer Patients: First Results of TESS Phase II Trial
    Location: Room 150
    Presenter: WeiWei Xiao, MD, PhD – Sun Yat-Sen University Cancer Center
  • 3:00 PM – 3:10 PM ET
    306 - Radiation Quality Control in the PROSPECT Trial
    Location: Room 150
    Presenter: Harvey Mamon, MD, PhD, FASTRO – Brigham and Women's Hospital/Dana-Farber
  • 3:10 PM – 3:20 PM ET
    307 - Patient Reported Quality of Life and Functional Outcomes after Pre-Operative Short- vs. Long-Course Radiotherapy for Rectal Adenocarcinoma
    Location: Room 150
    Presenter: Syed Shah, MD
  • 3:20 PM – 3:30 PM ET
    Discussant
    Location: Room 150
    Discussant: Emma Holliday, MD – The University of Texas MD Anderson Cancer Center
  • 2:30 PM – 2:40 PM ET
    296 - Induction Chemotherapy plus Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone in High-Risk Locally Advanced Cervical Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
    Location: Room 209
    Presenter: Hua Yang, MD – The First Affiliated Hospital of Air Force Medical University
  • 2:40 PM – 2:50 PM ET
    297 - Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial
    Location: Room 209
    Presenter: Loren Mell, MD, FASTRO – University of California, San Diego
  • 2:50 PM – 3:00 PM ET
    298 - IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
    Location: Room 209
    Presenter: Adam Grippin, MD, PhD – MD Anderson Cancer Center
  • 3:00 PM – 3:10 PM ET
    299 - Influence of Cachexia in Locally Advanced Endometrial Cancer: A Secondary Analysis of NRG GOG 258/RTOG 1203
    Location: Room 209
    Presenter: Eric Donnelly, MD – Northwestern Memorial Hospital
  • 3:10 PM – 3:20 PM ET
    300 - Comparison of Docetaxel and Cisplatin Concurrent and Short-Course Adjuvant Chemotherapy with Cisplatin Concurrent Chemotherapy in Radiotherapy for Locally Advanced Cervical Cancer: A Phase III Multice
    Location: Room 209
    Presenter: Ying Zhang
  • 3:20 PM – 3:30 PM ET
    301 - Five-Year Outcomes of a Phase II Study of Post-Operative Proton Beam Radiation for Gynecologic Cancers
    Location: Room 209
    Presenter: Andrea Russo, MD – Massachusetts General Hospital
  • 3:30 PM – 3:40 PM ET
    Discussant
    Location: Room 209
    Discussant: Kristin Bradley, MD – University of Wisconsin
  • 2:30 PM – 2:40 PM ET
    289 - Requirements and Study Design for the Next Proton Flash Clinical Trials: An International Multidisciplinary Delphi Consensus
    Location: Room 152
    Presenter: Yvonne Klaver, MD, PhD – HollandPTC
  • 2:40 PM – 2:50 PM ET
    290 - First Patient Study with Visual Biofeedback for Gating Delivery Efficiency Improvements on a 1.5 T MR-Linac
    Location: Room 152
    Presenter: Frederique van Gameren, MS – UMC Utrecht
  • 2:50 PM – 3:00 PM ET
    291 - A Sparse Uncollimated ? Counter Network for In Vivo Dose Reconstruction in 225Ac-Based Targeted Alpha Therapy
    Location: Room 152
    Presenter: Rahul Lall, MS, BS – University of California, Berkeley
  • 3:00 PM – 3:10 PM ET
    292 - A Ridge-Filter-Based and Group-Sparsity-Regularized (RFGS) Energy Layer Reduction Method for IMPT
    Location: Room 152
    Presenter: Hao Gao, PhD – University of Kansas Medical Center
  • 3:10 PM – 3:20 PM ET
    293 - Enhancing Proton ARC Treatment Efficiency with a Multi-Arc Approach
    Presenter: Hao Gao, PhD – University of Kansas Medical Center
  • 3:10 PM – 3:20 PM ET
    293 - Enhancing Proton ARC Treatment Efficiency with a Multi-Arc Approach
    Location: Room 152
    Presenter: Jiangjun Ma, PhD – Shanghai Jiao Tong University
  • 3:20 PM – 3:30 PM ET
    294 - AAPM GEC-ESTRO Task Group 342: An Update on Image-Guided Robotic Brachytherapy
    Location: Room 152
    Presenter: Tarun Podder, PhD – SUNY Upstate Medical University
  • 3:30 PM – 3:40 PM ET
    295 - Toward Augmented Reality-Driven MR-Guided Interstitial Brachytherapy
    Location: Room 152
    Presenter: Eric Paulson, PhD – Medical College of Wisconsin
  • 2:30 PM – 2:40 PM ET
    LBA08 - Outcomes and Immune Responses from INNATE: A Randomized Phase II Trial of Sotigalimab Immunotherapy during Neoadjuvant Therapy of Rectal Cancer
    Location: Room 207
    Presenter: Todd Aguilera, MD, PhD – UT Southwestern Medical Center
  • 2:40 PM – 2:50 PM ET
    LBA09 - Neoadjuvant Chemoradiation (CROSS) vs. Perioperative Chemotherapy (FLOT) in Esophageal Adenocarcinoma (EAC): ESOPEC - A Randomized Controlled Prospective Multicenter Phase III Trial
    Location: Room 207
    Presenter: Thomas Brunner, MD – Medical University Graz
  • 2:50 PM – 3:00 PM ET
    LBA10 - Outcomes of RAdium-223 and SABR vs. SABR for oligomEtastatic prostate caNcerS - The RAVENS Phase II Randomized Trial
    Location: Room 207
    Presenter: Ana Kiess, MD, PhD – Johns Hopkins University
  • 3:00 PM – 3:10 PM ET
    LBA11 - A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma
    Location: Room 207
    Presenter: Scott Bratman, MD, PhD – Princess Margaret Hospital
  • 3:10 PM – 3:20 PM ET
    LBA12 - Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-Label, Non-Inferio
    Location: Room 207
    Presenter: Linglong Tang, MD, PhD – Sun Yat-Sen University Cancer Center
  • 3:20 PM – 3:30 PM ET
    LBA13 - Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)
    Location: Room 207
    Presenter: Puneeth Iyengar, MD, PhD – Memorial Sloan Kettering Cancer Center
  • 3:30 PM – 3:40 PM ET
    LBA14 - Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial
    Location: Room 207
    Presenter: Feng-Ming Hsu, MD, PhD – National Taiwan University Hospital
  • 4:00 PM – 4:10 PM ET
    308 - Phase I/II Prospective Dose Escalation Trial with Proton-Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncolog
    Location: Room 207
    Presenter: Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital
  • 4:10 PM – 4:20 PM ET
    309 - Target Volume Delineation for the Re-Irradiation of Recurrent Glioblastoma: MRI- or PET-Based? Results of the GLIAA Prospective Randomized Trial
    Location: Room 207
    Presenter: Anca Grosu, MD – University of Freiburg
  • 4:20 PM – 4:30 PM ET
    310 - Safety and Preliminary Efficacy of AZD1390 + Radiation Therapy for Glioblastoma
    Location: Room 207
    Presenter: Jonathan Yang, MD, PhD – New York University School of Medicine
  • 4:30 PM – 4:40 PM ET
    311 - Cranial Neuropathy Outcomes Following Stereotactic Radiosurgery or Radiotherapy for Skull Base Meningioma
    Location: Room 207
    Presenter: Yazeed Kesbeh, MD – Southern California Permanente Medical Group
  • 4:40 PM – 4:50 PM ET
    Discussant
    Location: Room 207
    Discussant: Tony Wang, MD, FASTRO – Columbia University
  • 4:50 PM – 5:00 PM ET
    1132 - A Multi Institutional Study of the Impact of Reirradiation Dose for Recurrent High Grade Glioma
    Location: Room 207
    Presenter: Corbin Helis, MD
  • 4:00 PM – 4:10 PM ET
    317 - Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
    Location: Room 202
    Presenter: Amar Kishan, MD – UCLA Radiation Oncology
  • 4:10 PM – 4:20 PM ET
    318 - Volumetric Changes and Acute Toxicity with 68Ga Prostate-Specific Membrane Antigen vs 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial
    Location: Room 202
    Presenter: Vishal Dhere, MD – Emory University
  • 4:20 PM – 4:30 PM ET
    319 - Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prosp
    Location: Room 202
    Presenter: William Hall, MD – Medical College of Wisconsin (MCW)
  • 4:30 PM – 4:40 PM ET
    320 - Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage High Dose Rate Brachytherapy for Radiorecurrent Prostate Cancer (F-SHARP)
    Location: Room 202
    Presenter: Abhishek Solanki, MD, MS – Loyola University Chicago Stritch School of Medicine
  • 4:40 PM – 4:50 PM ET
    321 - Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
    Location: Room 202
    Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network
  • 4:50 PM – 5:00 PM ET
    322 - Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase I
    Location: Room 202
    Presenter: Andre Gouveia, MD – McMaster University
  • 4:00 PM – 4:10 PM ET
    312 - Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma - Long-Term Results of Expanded Cohort
    Location: Room 145
    Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
  • 4:10 PM – 4:20 PM ET
    313 - Quality of Life (QOL) of Patients with Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
    Location: Room 145
    Presenter: Minh Tam Truong, MD, MBA, MBBS, FASTRO – Boston University School of Medicine
  • 4:20 PM – 4:30 PM ET
    314 - HYHOPE: A Phase I Study of De-Intensified Hypofractionated Radiation Therapy for Human Papillomavirus-Associated Oropharynx Cancer
    Location: Room 145
    Presenter: Dominic Moon, MD – UT Southwestern Medical Center
  • 4:30 PM – 4:40 PM ET
    315 - HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
    Location: Room 145
    Presenter: Eric Stutheit-Zhao, MD, PhD – Princess Margaret Cancer Centre
  • 4:40 PM – 4:50 PM ET
    316 - The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamo
    Location: Room 145
    Presenter: Li Wang, MD, PhD – MD Anderson Cancer Center
  • 4:50 PM – 5:00 PM ET
    Discussant
    Location: Room 145
    Discussant: Lachlan McDowell, PhD, MBBS, FRANZCR – Princess Alexandra Hospital
  • 4:00 PM – 4:05 PM ET
    Introduction
    Location: Room 152
  • 4:05 PM – 4:10 PM ET
    1071 - MicroRNA-Based Germline Biomarkers of Pathologic Complete Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
    Location: Room 152
    Presenter: Joanne Weidhaas, MD, PhD – UCLA Radiation Oncology
  • 4:10 PM – 4:15 PM ET
    1072 - Sequential 90Y Selective Internal Radiation Therapy (SIRT) and Stereotactic Body Radiation Therapy (SBRT) Using 90Y PET-Based Absorbed Dose Maps: Interim Analysis of a Phase I St
    Location: Room 152
    Presenter: Daniel Polan, PhD – University of Michigan
  • 4:15 PM – 4:20 PM ET
    1073 - Comprehensive Geriatric Assessment Guided Radiotherapy in Older Patients with Locally Advanced Rectal Cancer - Results of a Multicenter Prospective Non-Operative Cohort Study
    Location: Room 152
    Presenter: Yuexin Yang, MD – Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital
  • 4:20 PM – 4:25 PM ET
    1074 - Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials
    Location: Room 152
    Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
  • 4:25 PM – 4:30 PM ET
    1075 - Patient Reported Outcomes after Chemoradiation with IMPT vs. IMRT for Patients with Anal Canal Squamous Cell Carcinoma
    Location: Room 152
    Presenter: Muhammad Shuja, MD – Mayo Clinic Rochester
  • 4:30 PM – 4:55 PM ET
    Questions and Answers
    Location: Room 152
  • 4:55 PM – 5:00 PM ET
    Closing
  • 4:00 PM – 4:05 PM ET
    Questions and Answers
    Location: Room 204
  • 4:05 PM – 4:10 PM ET
    1083 - Outcome and Pattern of Failure Following Definitive High-Dose Radiotherapy for PrImary Vulvar CancEr: Interim Analysis of The DRIVE Multicenter Cohort Study
    Location: Room 204
    Presenter: Anupam Rishi, MD – Moffitt Cancer Center
  • 4:10 PM – 4:15 PM ET
    1084 - A Prospective Single-Arm Study of Daily Online Adaptive Radiotherapy for Cervical Cancer with Reduced PTV Margin: Acute Toxicity Results
    Location: Room 204
    Presenter: Guangyu Wang, MD – Peking Union Medical College Hospital
  • 4:15 PM – 4:20 PM ET
    1085 - Efficacy of Induction Chemotherapy in the Treatment of Locally Advanced Cervical Cancer in Botswana
    Location: Room 204
    Presenter: Emily MacDuffie, MD – University of Pennsylvania
  • 4:20 PM – 4:25 PM ET
    1086 - Outcomes of Radiotherapy in the First-Line Treatment of Recurrent/Metastatic Cervical Cancer: A Multicenter, Retrospective Study
    Location: Room 204
    Presenter: Peng Xie – Shandong Cancer Hospital and Institute
  • 4:25 PM – 4:30 PM ET
    1087 - A Retrospective Comparison of Acute Toxicities in Patients Receiving Pelvic Radiation for Newly Diagnosed Gynecologic Primaries with Intensity Modulated Proton Therapy and Volume Modulated Arc Therapy
    Location: Room 204
    Presenter: Matthew Brown, MD – University of Maryland Radiation Oncology
  • 4:30 PM – 4:35 PM ET
    1088 - The Evaluation of Anxiety and Pain Levels in Patients Receiving Brachytherapy: Turkish Society For Radiation Oncology Brachytherapy Group Study (Brg-001)
    Location: Room 204
    Presenter: Ferah Yildiz, MD – Hacettepe University Medical School
  • 4:35 PM – 4:55 PM ET
    Questions and Answers
    Location: Room 204
  • 4:55 PM – 5:00 PM ET
    Closing
    Location: Room 204
  • 4:00 PM – 4:05 PM ET
    Introduction
    Location: Room 209
  • 4:05 PM – 4:10 PM ET
    1077 - Routine Physics Work Efficacy and Efficiency Improvement with Duty Shared Among Daily Physicist Group for a Multi Hospital Radiation Oncology Network
    Location: Room 209
    Presenter: Eric Paulson, PhD – Medical College of Wisconsin
  • 4:10 PM – 4:20 PM ET
    1078 - Detecting and Classifying On-Treatment Patient Shifts, with In-Vivo EPID Images and Deep Learning
    Location: Room 209
    Presenter: Casey Bojechko, PhD – University of California San Diego
  • 4:15 PM – 4:20 PM ET
    1079 - Automatic Large-Scale Prospective Monitoring and Blind Evaluation of the Performance of Commercial AI Auto-Segmentation in Routine Clinical Practice: Preliminary Results for a Cohort of Breast Cancer
    Location: Room 209
    Presenter: Piotr Dubrowski, MS, MCCPM – Stanford University
  • 4:20 PM – 4:25 PM ET
    1080 - Parallel Prospective Plan of Care Reviews: Evolution over Five Years and Future Directions
    Location: Room 209
    Presenter: Samuel Chao, MD, FASTRO – Cleveland Clinic Taussig Cancer Center
  • 4:25 PM – 4:30 PM ET
    1081 - Systematic Review of Quality Assurance Metrics Used to Standardize Target and Organ at Risk Contours on Cooperative Group Clinical Trials
    Location: Room 209
    Presenter: Leila Tchelebi, MD – Northern Westchester Hospital
  • 4:30 PM – 4:35 PM ET
    1082 - Impact of Standardized Structure Templates on Violations for Radiation Plans Submitted to Co-Operative Group Clinical Trials
    Location: Room 209
    Presenter: Gobind Gill, MD – University of Alabama at Birmingham
  • 4:35 PM – 4:55 PM ET
    Questions and Answers
    Location: Room 209
  • 4:55 PM – 5:00 PM ET
    Closing
    Location: Room 209
  • 5:15 PM – 5:25 PM ET
    328 - Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)
    Location: Room 146
    Presenter: Julie Bauman, MD – George Washington University Cancer Center
  • 5:25 PM – 5:35 PM ET
    329 - Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and
    Location: Room 146
    Presenter: German Corredor, PhD, MS – Emory University
  • 5:35 PM – 5:45 PM ET
    330 - Tumor Hypoxia on 18F-Fluoromisonidazole Positive Emission Tomography as a Predictor of Distant Metastasis-Free Survival after Chemoradiation for Head and Neck Squamous Cell Carcinoma: A Pooled Analysi
    Location: Room 146
    Presenter: Chengcheng Gui, MD – Memorial Sloan Kettering Cancer Center
  • 5:45 PM – 5:55 PM ET
    331 - Imaging Metrics and HPV ctDNA Kinetics in a Phase II Immuno-Chemoradiation Trial for Locoregionally Advanced p16+ Oropharynx Cancer
    Location: Room 146
    Presenter: Samuel Regan, MD – University of Michigan
  • 5:55 PM – 6:05 PM ET
    332 - Chromosomal Instability as a Prognostic Biomarker for Local Failure in Laryngeal Carcinoma Patients Treated with Definitive Radiation in NRG/RTOG 9512
    Location: Room 146
    Presenter: Pippa Cosper, MD, PhD – University of Wisconsin Madison
  • 6:05 PM – 6:15 PM ET
    Discussant
    Location: Room 146
    Discussant: Zain Husain, MD – Southern California Permanente Medical Group
  • 5:15 PM – 5:25 PM ET
    323 - Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans: An Independent Review Entity and Call for Action
    Location: Room 144
    Presenter: Jared Pasetsky, MD – New York Presbyterian Hospital Columbia Campus
  • 5:25 PM – 5:35 PM ET
    324 - Intrafraction Virtual Reality-Based Environment Modifications Impact on Procedural Anxiety, Heart Rate and External Beam Radiotherapy Experience
    Location: Room 144
    Presenter: Conley Kriegler, MD – University of Alberta
  • 5:35 PM – 5:45 PM ET
    325 - Cost-Effectiveness of Stereotactic Body Radiotherapy vs. Thermal Ablation for Primary Renal Cell Carcinoma: Analysis of the FASTRACK II Trial
    Location: Room 144
    Presenter: Shankar Siva, PhD, MBBS, FRANZCR – Peter MacCallum Cancer Centre
  • 5:45 PM – 5:55 PM ET
    326 - Medical Misinformation about Cancer Recurrence Risks in Patients with Breast Cancer Who Received Radiation
    Location: Room 144
    Presenter: Fumiko Chino, MD – MD Anderson Cancer Center
  • 5:55 PM – 6:05 PM ET
    327 - Prevalence of Control Arm Overperformance as a Contributing Factor to Optimism Bias in Phase 3 Oncology Clinical Trials
    Location: Room 144
    Presenter: Ansel Nalin, MD, PhD – MD Anderson Cancer Center
  • 6:05 PM – 6:15 PM ET
    Discussant
    Location: Room 144
    Discussant: Robin Yabroff, PhD, MBA – American Cancer Society
  • 5:15 PM – 5:20 PM ET
    Introduction
    Location: Room 151
  • 5:20 PM – 5:25 PM ET
    1089 - Genomic Signature for Leptomeningeal Progression in Brain Metastasis Patients Using Liquid Biopsy-Acquired Comprehensive Genomic Profiling
    Location: Room 151
    Presenter: Claire Lanier, MD – Wake Forest School of Medicine
  • 5:25 PM – 5:30 PM ET
    1090 - Cost-Effectiveness of Proton Craniospinal Irradiation (pCSI) in Patients with Solid Tumor Leptomeningeal Metastasis
    Location: Room 151
    Presenter: Anna Dornisch, MD – UC San Diego
  • 5:30 PM – 5:35 PM ET
    1091 - Characterization of Focal Leptomeningeal Disease among Patients with Brain Metastases: A Novel Entity
    Location: Room 151
    Presenter: Nayan Lamba, MD – Harvard Radiation Oncology Program
  • 5:35 PM – 5:40 PM ET
    1092 - Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy: A Single-Institution Analysis of 534 Resected Metastases
    Location: Room 151
    Presenter: Haley Perlow, MD – Case Western Reserve University/University Hospitals Cleveland Medical Center
  • 5:40 PM – 5:45 PM ET
    1093 - Maximum Tolerated Dose of Neoadjuvant Stereotactic Radiosurgery and Post-Treatment Immune Profiling for Metastatic Brain Tumors: Results of a Phase I Dose Escalation Trial
    Location: Room 151
    Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center
  • 5:45 PM – 5:50 PM ET
    1094 - Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations
    Location: Room 151
    Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center
  • 5:50 PM – 6:10 PM ET
    Questions and Answers
    Location: Room 151
  • 6:10 PM – 6:15 PM ET
    Closing
    Location: Room 151
  • 5:15 PM – 5:20 PM ET
    Introduction
    Location: Room 152
  • 5:20 PM – 5:25 PM ET
    1101 - Cu-64-Anti-CEA M5A as a Novel Theranostics PET Imaging Agent Pre and Post Neoadjuvant Radiotherapy in Advanced Rectal Cancer
    Location: Room 152
    Presenter: Jeffrey Wong, MD, FASTRO – City of Hope National Medical Center
  • 5:25 PM – 5:30 PM ET
    1102 - Luminal B Single-Cell Signature and Resistance to Hormone Therapy in Breast Cancer
    Location: Room 152
    Presenter: William Chen, MD – UCSF
  • 5:30 PM – 5:35 PM ET
    1103 - Genomic Predictors of Response to Metastasis Directed Therapy with or without Androgen Deprivation Therapy
    Location: Room 152
    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center
  • 5:35 PM – 5:40 PM ET
    1104 - Urine Cell-Free DNA Analysis to Detect Tumor Tissue of Origin and Predict Pathologic Complete Response across Genitourinary Malignancies
    Location: Room 152
    Presenter: Pradeep Chauhan, PhD – Mayo Clinic Rochester
  • 5:40 PM – 5:45 PM ET
    1105 - Genomic Characterization of Radiotherapy-Associated Muscle Invasive Bladder Cancer after Prostate Cancer Treatment
    Location: Room 152
    Presenter: N. Ari Wijetunga, MD, PhD, MS – University of North Carolina
  • 5:45 PM – 5:50 PM ET
    1106 - Impact of Cancer Therapy on Clonal Hematopoiesis Mutations and Subsequent Clinical Outcomes
    Location: Room 152
    Presenter: Kevin Nead, MD, MPhil – MD Anderson Cancer Center
  • 5:50 PM – 6:10 PM ET
    Questions and Answers
    Location: Room 152
  • 6:10 PM – 6:15 PM ET
    Closing
    Location: Room 152
  • 5:15 PM – 5:20 PM ET
    Introduction
    Location: Room 147
  • 5:20 PM – 5:25 PM ET
    1095 - Real-Time Onboard Volumetric Imaging for Tumor Tracking during Treatment and Post-Treatment Dose Verification
    Location: Room 147
    Presenter: Xiaofeng Yang, PhD – Emory University
  • 5:25 PM – 5:30 PM ET
    1096 - Automated Segmentation of Pancreatic Tumor Microvasculature in High-Resolution Optical Coherence Tomography (OCT) Using Pre-Trained Large-Scale Supervised Networks for Early Evaluation of Radiation Th
    Location: Room 147
    Presenter: Elham Abouei, PhD – Emory University
  • 5:30 PM – 5:35 PM ET
    1097 - Ultrafast Short-Arc Diffusion-Based Cone Beam CT Image Reconstruction
    Location: Room 147
    Presenter: Xiang Li, PhD – Memorial Sloan Kettering Cancer Center
  • 5:35 PM – 5:40 PM ET
    1098 - Quantification of Local-Regional Deformation Based on Cherenkov Imaged Vasculature for Breast Radiotherapy Patients
    Location: Room 147
    Presenter: Yao Chen, BS – Dartmouth College
  • 5:40 PM – 5:45 PM ET
    1099 - The Novel Assessment of Stereotactic Body Radiotherapy (SBRT) for Cardiac Radioablation to the Cavotricuspid Isthmus by 13C Pyruvate Metabolic Imaging and Redox Reaction Imaging Using Dynamic Nuclear
    Location: Room 147
    Presenter: Masayuki Matsuo, MD, PhD – Gifu University
  • 5:45 PM – 5:50 PM ET
    1100 - Orthogonal 2D MR Imaging and Manifold Learning Enables Real-Time 3D Tumor Tracking
    Location: Room 147
    Presenter: John Ginn, PhD – Duke University School of Medicine
  • 6:10 PM – 6:15 PM ET
    Closing
    Location: Room 147
  • Wednesday, October 2, 2024
  • 8:00 AM – 8:10 AM ET
    334 - Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oliogmetastatic Castration-Sensitive Prostate Cancer, including in Patients from the STOMP and ORIOLE Phase II Rando
    Location: Room 207
    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center
  • 8:10 AM – 8:20 AM ET
    333 - A Digital Pathology Multimodal Artificial Intelligence Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer
    Location: Room 207
    Presenter: Yang Song, PhD – University of Maryland
  • 8:20 AM – 8:30 AM ET
    335 - A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)
    Location: Room 207
    Presenter: Kosj Yamoah, MD, PhD – H. Lee Moffitt Cancer Center and Research Institute
  • 8:30 AM – 8:40 AM ET
    336 - Examination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage
    Location: Room 207
    Presenter: Shalini Moningi, MD – Brigham and Women's Hospital/Dana-Farber
  • 8:40 AM – 8:50 AM ET
    337 - The Interplay between Acute and Late Toxicity among Patients Receiving Prostate Radiotherapy: A Pooled Analysis of 7 Randomized Trials
    Location: Room 207
    Presenter: John Nikitas, MD – UCLA Radiation Oncology
  • 8:50 AM – 9:00 AM ET
    338 - Prostate Cancer Integrated Risk Evaluation (P-CARE): A Model to Stratify Risk of Any, Metastatic, and Fatal Prostate Cancer
    Location: Room 207
    Presenter: Anna Dornisch, MD – UC San Diego
  • 8:00 AM – 8:10 AM ET
    339 - FLASH Proton Radiotherapy on a Model of Radiation-Induced Myocardial Fibrosis
    Location: Room 143
    Presenter: Ioannis Verginadis, PhD, MS – University of Pennsylvania
  • 8:10 AM – 8:20 AM ET
    340 - Contribution of Cardiac Macrophages and Interferon Signaling to the Therapeutic Effects of Cardiac Radiation in Heart Failure
    Location: Room 143
    Presenter: Lauren Pedersen, PhD – Washington University School of Medicine
  • 8:20 AM – 8:30 AM ET
    341 - Targeting Angiotensin and Inflammation to Prevent Radiotherapy-Induced Bladder Toxicity
    Location: Room 143
    Presenter: Brian Marples, PhD, FASTRO – University of Rochester
  • 8:30 AM – 8:40 AM ET
    342 - Gut Microbiota and Radiation Induced Intestine Injury through Modulating Tissue Resident Macrophage Homeostasis
    Location: Room 143
    Presenter: Yue Zhao, MD, PhD – China
  • 8:40 AM – 8:50 AM ET
    343 - Targeting mettl3 to Reglate p53 Oscillatory Activation Promotes DNA Damage Repair in Intestinal Stem Cells after Radiation
    Location: Room 143
    Presenter: Ruiqiu Zhu, MD, PhD – Soochow University
  • 8:50 AM – 9:00 AM ET
    344 - Effects of DKK3 on radiation-induced inflammatory and fibrosing skin damage
    Location: Room 143
    Presenter: Peter Huber, MD, PhD – German Cancer Research Center (DKFZ)
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 204
  • 8:05 AM – 8:10 AM ET
    1109 - A Novel Comprehensive Multi-Omic Biosignature to Assess Recurrence Risk and Adjuvant Therapy Benefit in Early-Stage Hormone-Positive Invasive Breast Cancer Patients
    Location: Room 204
    Presenter: Naamit Gerber, MD – NYU Langone Medical Center
  • 8:10 AM – 8:15 AM ET
    1110 - Toxicity after Proton Beam Therapy for New and Recurrent Breast Cancer
    Location: Room 204
    Presenter: Madeline Schumacher, BS – University of Cincinnati College of Medicine
  • 8:15 AM – 8:20 AM ET
    1111 - Pre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients
    Location: Room 204
    Presenter: Molly Chakraborty, BSE – Rutgers New Jersey Medical School
  • 8:20 AM – 8:25 AM ET
    1112 - Clinical Characteristics of Breast Cancer Patients with Lung Changes Following Intensity Modulated Proton Therapy
    Location: Room 204
    Presenter: Matthew Case, MD – Emory University
  • 8:25 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 204
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 204
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 144
  • 8:05 AM – 8:10 AM ET
    1119 - Normalization of Lactate Dehydrogenase (LDH) as a Potential Prognostic Factor for Relapsed/Refractory Aggressive B-Cell Lymphoma (R/R BCL) Patients Receiving CAR T Following Bridging Radiotherapy: Res
    Location: Room 144
    Presenter: Monica Chelius, MD – University of Pennsylvania
  • 8:10 AM – 8:15 AM ET
    1120 - Salvage Radiotherapy in LBCL After First Line Chemo-immunotherapy: Can We Avoid CAR-T Therapy?
    Location: Room 144
    Presenter: Jessica Brady, MD, MB, ChB – Guy's and St. Thomas' NHS Foundation Trust
  • 8:15 AM – 8:20 AM ET
    1121 - Patterns of Failure in Multiple Myeloma with Extramedullary Disease Following Anti-BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Location: Room 144
    Presenter: Justyn Nakashima, DO – Moffitt Cancer Center
  • 8:20 AM – 8:25 AM ET
    1122 - Radiation Therapy as a Bridging Strategy in CAR-T Cell Therapy and the Impact of Tumor Control Status at CAR-T Cell Infusion
    Location: Room 144
    Presenter: Takuya Shimizuguchi, MD – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
  • 8:25 AM – 8:30 AM ET
    1123 - Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) as Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas
    Location: Room 144
    Presenter: Tanooha Veeramachaneni, BS – UT Southwestern Medical School
  • 8:30 AM – 8:35 AM ET
    1124 - Results of a Comprehensive Prospective Protocol of Radiotherapy Bridging and Consolidation for CAR T in Large B Cell Lymphoma (RESTART)
    Location: Room 144
    Presenter: George Mikhaeel, MD, MBBS – Guy's Cancer Center
  • 8:35 AM – 8:55 AM ET
    Questions & Answers
    Location: Room 144
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 144
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 147
  • 8:05 AM – 8:10 AM ET
    1113 - Applying GD-EOB-DTPA Enhanced MR to Unveil the Radiobiological Effect of Proton and Photon Therapy Based on the Longitudinal Evolution of the Focal Liver Reaction
    Location: Room 147
    Presenter: Haohua Wang
  • 8:10 AM – 8:15 AM ET
    1114 - Incorporating Predicted Weekly Anatomies into IMPT Robust Optimization in Nasopharyngeal Cancers
    Location: Room 147
    Presenter: Mark Ka Heng Chan, PhD – University Nebraska Medical Center
  • 8:15 AM – 8:20 AM ET
    1115 - Plan-Specific Range Tolerance Method for CBCT Triggered Adaptive Plans in Intensity Modulated Proton Therapy: Pilot Study on Head and Neck
    Location: Room 147
    Presenter: Weiguang Yao, PhD – University of Maryland School of Medicine, Baltimore
  • 8:20 AM – 8:25 AM ET
    1116 - Assessing Dose Uncertainties in Cardiac SBRT due to Cardiorespiratory Motion: Photon vs. Proton Therapy Comparison
    Location: Room 147
    Presenter: Guangjun Li, PhD – West China Hospital of Sichuan University
  • 8:25 AM – 8:30 AM ET
    1117 - A New RBE Optimization Method with Iterative Jacobian-Based Linearization for Carbon Ion Radiation Therapy
    Location: Room 147
    Presenter: Chao Wang, PhD – University of Kansas Medical Center
  • 8:30 AM – 8:35 AM ET
    1118 - Split Field IMPT Optimization to Maximize OAR Dose Rate and Implications for the Minimal FLASH Effect
    Location: Room 147
    Presenter: Ke Sheng, PhD – University of California, San Francisco
  • 8:35 AM – 8:55 AM ET
    Questions and Answers
    Location: Room 147
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 147
  • 8:00 AM – 8:05 AM ET
    Introduction
    Location: Room 145
  • 8:05 AM – 8:10 AM ET
    1125 - Assessing the Feasibility and Dosimetric Impact of a Non-Animal Stabilized Hyaluronic Acid (NASHA) Rectal Spacer in High-Dose-Rate Brachytherapy for Prostate Cancer
    Location: Room 145
    Presenter: Reema Patel, BS – University of Virginia School of Medicine
  • 8:10 AM – 8:15 AM ET
    1126 - CT Dosimetry in Radioembolization: Image Acquisition Considerations
    Location: Room 145
    Presenter: Alasdair Syme, PhD – Nova Scotia Health Authority
  • 8:15 AM – 8:20 AM ET
    1127 - Prediction of Radiotherapy Efficacy of Esophageal Cancer Using Radiomics Temporal Sequence Extracted from Weekly CBCT
    Location: Room 145
    Presenter: Hui Wu, MD, PhD – Henan Cancer Hospital
  • 8:20 AM – 8:25 AM ET
    1128 - Novel Introduction of In Vivo Dynamic Nuclear Polarized MRI for the Visual Verification of IMRT
    Location: Room 145
    Presenter: Takayuki Mori, MD – Gifu University School of Medicine
  • 8:25 AM – 8:30 AM ET
    1129 - A Multi-Center Study on the Clinical Deliverability of Fully Automated Planning for Stereotactic Body Radiation Therapy in Lung Cancer Using a Deep Learning Transfer Method
    Location: Room 145
    Presenter: Jinghui Pan, PhD, MS – Renmin Hospital of Wuhan University
  • 8:30 AM – 8:35 AM ET
    1130 - Development of a Predictive Model for Rectal Toxicity in Prostate Cancer
    Location: Room 145
    Presenter: Ibrahim Chamseddine, PhD – Massachusetts General Hospital, Harvard Medical School
  • 8:35 AM – 8:55 AM ET
    Questions & Answers
    Location: Room 145
  • 8:55 AM – 9:00 AM ET
    Closing
    Location: Room 145
  • 9:15 AM – 9:35 AM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Jan Seuntjens, PhD – Princess Margaret Cancer Centre, University Health Network, University of Toronto
  • 9:35 AM – 9:55 AM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Charu Aggarwal, MD – University of Pennsylvania
  • 9:55 AM – 10:15 AM ET
    Discussant
    Location: Ballroom A/B/C
    Discussant: Matthias Guckenberger, MD – University Zurich and University Hospital Zurich
  • 10:30 AM – 10:40 AM ET
    1131 - Macropathology and Multimodal Magnetic Resonance Image Based Deep Learning Model for Personalized Definition of Target Volume in Patients with Glioma
    Location: Room 151
    Presenter: Nie Shulun, MD, PhD – Shandong Cancer Hospital and Institute
  • 10:40 AM – 10:50 AM ET
    1133 - Defining the Occult Margin in Recurrent Glioblastoma Using Spectroscopic MRI: Implications for Radiation Therapy Volumes
    Location: Room 151
    Presenter: Eric Mellon, MD, PhD – University of Miami
  • 10:50 AM – 11:00 AM ET
    1134 - Histologic Classifier of Radiosensitivity to Spine SBRT
    Location: Room 151
    Presenter: Christopher Jackson, MD, MS – Memorial Sloan Kettering Cancer Center
  • 11:00 AM – 11:10 AM ET
    1135 - Analysis of Late Cognitive Outcomes after Whole Brain Radiotherapy and Radiosurgery for Brain Metastases in the North Central Cancer Treatment Group (NCCTG) N0574 and N107C Clinical Trials
    Location: Room 151
    Presenter: Alan Nichol, MD, FRCPC – BC Cancer - Vancouver Centre
  • 11:10 AM – 11:20 AM ET
    1136 - Clinical Endpoints Correlation with Molecular Features in the NRG Oncology/RTOG 9802 Low-Grade Glioma, Low-Risk Observation Arm
    Location: Room 151
    Presenter: Jessica Fleming, PhD – The Ohio State University
  • 11:20 AM – 11:30 AM ET
    2614 - Metabolic Profiling of Adult and Pediatric Glioma Tumor Samples Uncovers Intrinsic Metabolic Differences between Adult Glioblastomas and Pediatric High-Grade Histone H3 Mutant Gliomas
    Location: Room 151
    Presenter: Vladislav Sviderskiy, MD, PhD – Washington University School of Medicine in St. Louis
  • 10:30 AM – 10:35 AM ET
    Introduction
    Location: Room 143
  • 10:35 AM – 10:40 AM ET
    1137 - Impact of Aging on the Efficacy of Radiotherapy Combined with Immunotherapy and its Mechanism in a Mouse Model of Rectal Cancer
    Location: Room 143
    Presenter: Yan Wang, MD, PhD – Fudan University Shanghai Cancer Center
  • 10:40 AM – 10:45 AM ET
    1138 - Bcl-2 Inhibitor Combined with Radiotherapy and Anti-Tumor Immune Response through Inducing Immunogenic Cell Death
    Location: Room 143
    Presenter: Mengmeng Ma, MD
  • 10:45 AM – 10:50 AM ET
    1139 - Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation during Curative Radiotherapy
    Location: Room 143
    Presenter: Badr Id Said, MD, MS – MD Anderson Cancer Center
  • 10:50 AM – 10:55 AM ET
    1140 - Perturbation of Gut Microbiota Modulated the Abscopal Effects of Immunoradiotherapy in Rectal Cancer.
    Location: Room 143
    Presenter: Zhuang Xue, MD
  • 10:55 AM – 11:00 AM ET
    1141 - TIGIT Inhibitor Combined with Local Radiotherapy and PD-1 Inhibitor in a Syngenic Breast Cancer Model
    Location: Room 143
    Presenter: In Ah Kim, MD, PhD – Seoul National University
  • 11:00 AM – 11:05 AM ET
    1142 - Macrophages Play Key Role in Protecting Salivary Glands from Radiation Induced Damage
    Location: Room 143
    Presenter: Randall Kimple, MD, PhD, MBA, FASTRO – Univ of Wisconsin
  • 11:05 AM – 11:25 AM ET
    Questions and Answers
    Location: Room 143
  • 11:25 AM – 11:30 AM ET
    Closing
    Location: Room 143
  • 10:30 AM – 10:40 AM ET
    351 - Multi-Institutional Comparison of Ablative 5-Fraction MR-Guided Online Adapted vs. 15/25-Fraction CT-Guided Offline Adapted Radiation Therapy for Locally Advanced Pancreas Cancer
    Location: Room 144
    Presenter: Michael Chuong, MD – Miami Cancer Institute
  • 10:40 AM – 10:50 AM ET
    352 - The Effect of Tumor Biological Effective Dose (BED) on Stereotactic Body Radiotherapy (SBRT) Outcomes for Locally Advanced Cholangiocarcinoma (CCA): An Analysis of the ABC-07 Randomized Trial
    Location: Room 144
    Presenter: Maria Hawkins, MD – University College London
  • 10:50 AM – 11:00 AM ET
    353 - Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma
    Location: Room 144
    Presenter: Kenneth Merrell, MD, MS – Mayo Clinic Alix School of Medicine
  • 11:00 AM – 11:10 AM ET
    Discussant
    Location: Room 144
    Discussant: Parag Parikh, MD, BSE – Henry Ford Hospital
  • 11:10 AM – 11:20 AM ET
    354 - NRG Oncology International Consensus Atlas on Target Volumes for Dose-Escalated Pancreatic Cancer Radiotherapy
    Location: Room 144
    Presenter: Nina Sanford, MD – UT Southwestern Medical Center
  • 11:20 AM – 11:30 AM ET
    355 - Survival Prediction with Albumin-Bilirubin (ALBI) Changes in Hepatocellular Carcinoma Patients Treated with External Beam Radiotherapy (EBRT)
    Location: Room 144
    Presenter: Smith Apisarnthanarax, MD – University of Washington
  • 11:30 AM – 11:40 AM ET
    Discussant
    Location: Room 144
    Discussant: Kimberly Johung, MD, PhD – Yale University School of Medicine
  • 10:30 AM – 10:40 AM ET
    345 - Commissioning, Quality Assurance, and First Canine Treatment with a Conformal Proton Flash Delivery System
    Location: Room 145
    Presenter: Eric Diffenderfer, PhD – University of Pennsylvania
  • 10:40 AM – 10:50 AM ET
    346 - Multi-Contrast MRI Acceleration with K-Space Progressive Learning and Image-Space Self-to-Peer Aggregation
    Location: Room 145
    Presenter: Lianli Liu, PhD – Stanford University
  • 10:50 AM – 11:00 AM ET
    347 - Longitudinal Trends in Myocardial Metabolism following Non-Invasive Cardiac Radioablation for Ventricular Tachycardia Using PET-CT
    Location: Room 145
    Presenter: Carmen Bergom, MD, PhD – Washington University School of Medicine
  • 11:00 AM – 11:10 AM ET
    348 - Scintillation Imaging Dosimetry for High-Temporal Resolution Error Detection During UHDR Proton Beam Delivery
    Location: Room 145
    Presenter: Megan Clark, BS – Dartmouth College
  • 11:10 AM – 11:20 AM ET
    349 - Predicting Radiation Pneumonitis with Robust 4DCT-Ventilation and 4DCT-Perfusion Imaging Using Prospective Lung Cancer Clinical Trial Data
    Location: Room 145
    Presenter: Taindra Neupane, PhD – Sidney Kimmel Cancer Center at Thomas Jefferson University
  • 11:20 AM – 11:30 AM ET
    350 - Artificial Intelligence-Assisted Quantitative CT Analysis of Airway Changes Following SABR for Central Lung Tumors
    Location: Room 145
    Presenter: Omar Bohoudi, PhD – Amsterdam UMC location VUMC
  • 12:30 PM – 12:35 PM ET
    Introduction
    Location: Room 151
  • 12:35 PM – 12:40 PM ET
    1149 - Immunological effectiveness of carbon ion radiotherapy in pancreatic cancer
    Location: Room 151
    Presenter: Brett Bell, MS – Albert Einstein College of Medicine
  • 12:40 PM – 12:45 PM ET
    1150 - Investigating the Roles of the Epithelial-Mesenchymal Transition Program in Small Cell Lung Cancer Tumorigenesis and Chemoradiation Response
    Location: Room 151
    Presenter: Triet Nguyen, BA – Johns Hopkins Medicine
  • 12:45 PM – 12:50 PM ET
    1151 - Oral Bifidobacterium Longum BL21 Supplements in the Prevention of Acute Radiation-induced Intestinal Injury: A Single-Arm, Phase 2 Trial
    Location: Room 151
    Presenter: Ruiqiu Zhu, MD, PhD – Soochow University
  • 12:50 PM – 12:55 PM ET
    1152 - Radiotherapy-Induced Tumor Cell Senescence Reprograms Anti-Tumor Immunity in a p21 Dependent Manner
    Location: Room 151
    Presenter: Zengfu Zhang, MD – Shandong Cancer Hospital and Institute
  • 12:55 PM – 1:00 PM ET
    1153 - Molecular Mechanisms Underlying Liver Metastasis in Hypofractionated Radiotherapy-Resistant Colorectal Cancer
    Location: Room 151
    Presenter: Weitao Wen, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University
  • 1:00 PM – 1:05 PM ET
    1154 - A Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers
    Location: Room 151
    Presenter: Michael Spiotto, MD, PhD – The University of Texas MD Anderson Cancer Center
  • 1:05 PM – 1:25 PM ET
    Questions and Answers
    Location: Room 151
  • 1:25 PM – 1:30 PM ET
    Closing
    Location: Room 151
  • 12:30 PM – 12:35 PM ET
    Introduction
    Location: Room 144
  • 12:35 PM – 12:40 PM ET
    1143 - Rethinking Breast Irradiation Using Volumetric Modulated Arc Therapy with the Integration of Static Angle Ports and Dynamic Collimator
    Location: Room 144
    Presenter: Emily Hubley, MS, DABR – University of Pennsylvania
  • 12:40 PM – 12:45 PM ET
    1144 - Development of Prediction Model for Right and Left Liver Hypertrophy to Estimate Response in Patients Treatments Simulated with Photon Based 3DCRT and IMRT Plans
    Location: Room 144
    Presenter: Aashish Gupta, MS – UT MD Anderson Cancer Center
  • 12:45 PM – 12:50 PM ET
    1145 - Institution Volumetric Modulated Arc Therapy Total Body Irradiation Technique Using Autoplanning Scripts: 4 Year Experience
    Location: Room 144
    Presenter: Nataliya Kovalchuk, PhD – Stanford Cancer Institute Palo Alto
  • 12:50 PM – 12:55 PM ET
    1146 - Deep Learning-Based Dose Prediction for Thoracic Radiation in a Statewide Radiation Oncology Quality Consortium
    Location: Room 144
    Presenter: Daniel Polan, PhD – University of Michigan
  • 12:55 PM – 1:00 PM ET
    1147 - Clinical Implementation of an Automated VMAT Treatment Planning Script for Head and Neck Cancer Patients: 3 Year-Experience
    Location: Room 144
    Presenter: Nataliya Kovalchuk, PhD – Stanford Cancer Institute Palo Alto
  • 1:00 PM – 1:05 PM ET
    1148 - General and Organ Specific Consensus Recommendations for Stereotactic Body Radiotherapy Dose Prescription according to ICRU Report 91 from Working Groups on Stereotactic Radiotherapy
    Location: Room 144
    Presenter: Thomas Brunner, MD – Medical University Graz
  • 1:05 PM – 1:25 PM ET
    Questions and Answers
    Location: Room 144
  • 1:25 PM – 1:30 PM ET
    Closing
    Location: Room 144
  • 12:30 PM – 12:35 PM ET
    Introduction
    Location: Room 143
  • 12:35 PM – 12:40 PM ET
    1155 - Patient 2D Imaging and Enhancement with a Novel Dual-Layer Kv Imager
    Location: Room 143
    Presenter: Dianne Ferguson, PhD, DABR – Brigham and Women's Hospital/Dana Farber Cancer Institute
  • 12:40 PM – 12:45 PM ET
    1156 - Metal Identification and Artifact Reduction Using a Dual-Layer CBCT Imager Prototype
    Location: Room 143
    Presenter: Matthew Jacobson, PhD – DFCI
  • 12:45 PM – 12:50 PM ET
    1157 - A Pilot Trial Testing a Novel 2D Antiscatter Grid and Quantitative CBCT Pipeline: An Interim Quantitative Image Quality Analysis
    Location: Room 143
  • 12:50 PM – 12:55 PM ET
    1158 - Optimizing Target and Diaphragmatic Configuration, and Dosimetric Benefits Using Continuous Positive Airway Pressure (CPAP) in Stereotactic Ablative Radiotherapy for Lung Tumors
    Location: Room 143
    Presenter: Jung Bin Park, MD – Seoul National University College of Medicine
  • 12:55 PM – 1:00 PM ET
    1159 - Addressing the Impact of Skin Pigmentation on Quantitative Cherenkov Dosimetry in the First Diverse Patient Imaging Study
    Location: Room 143
    Presenter: Savannah Decker, PhD, BS – UC San Diego Health
  • 1:00 PM – 1:05 PM ET
    1160 - Efficacy of Thermoplastic Mask Heating before Radiotherapy in Reducing Setup Error for Patients with Gynecological Tumor: A Randomized Controlled Study
    Location: Room 143
    Presenter: Rong Wang
  • 1:05 PM – 1:25 PM ET
    Questions and Answers
    Location: Room 143
  • 1:25 PM – 1:30 PM ET
    Closing
    Location: Room 143